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Hebert: Opening a Can of Genetically-Modified Worms: Funding and Regulati

OPENING A CAN OF GENETICALLYMODIFIED WORMS: FUNDING AND
REGULATING CRISPR TECHNOLOGY
I. INTRODUCTION
Recent advances in biotechnology have led to a revolutionary process
in which scientists are able to edit the genes of an organism with
unprecedented accuracy, speed, and affordability. 1 This technological
process can come from different gene-editing technologies such as
CRISPR/Cas9 or CRISPR, which stands for Clustered Regularly
Interspaced Short Palindromic Repeats.2 The potential benefits of CRISPR
are expansive and could redirect how we treat genetic diseases. 3 Of
course, a powerful technology like CRISPR raises serious ethical questions
about how it should and should not be used.4 While many agree that our
society would benefit immeasurably from CRISPR, we must first ask
ourselves how far we are willing to go to achieve such desired results. 5
See CRISPR Timeline, BROAD INSTITUTE https://www.broadinstitute.org/what-broad/
areas-focus/project-spotlight/crispr-timeline [https://perma.cc/ZAE2-ZESZ] (providing
the timeline leading up through the advent of CRISPR). The natural process of CRISPR was
discovered in the early 1990s, but was not realized as a technological tool for scientists until
2012. Id. Currently, CRISPR aims to cure a rare eye disease called Leber congenital
amaurosis. Id. Antonio Regaledo, CRISPR Gene Editing to be Tested on People by 2017, MIT
TECH. REV. (Nov. 5, 2015), https://www.technologyreview.com/s/543181/crispr-geneediting-to-be-tested-on-people-by-2017-says-editas/
[https://perma.cc/LS5E-PN29].
Scientists are striving to cure a large variety of genetic diseases in the coming years and
believe that a cure for cancer is not out of reach in the near future. Id.
2
See Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive
Bacterial Immunity, 337 SCIENCE MAG. 816–21, http://science.sciencemag.org/content/337/
6096/816.full.pdf+html [https://perma.cc/THZ4-5LZX] (discussing the discovery of the
CRISPR/Cas system discovery). CRISPR stands for Clustered Regularly Interspaced Short
Palindromic Repeats. Id. The process is an evolved adaptation in bacteria used to fight off
viruses. Id. A deeper discussion on what CRISPR is and how it works will be discussed
below. See also infra Part II.B (discussing the process of gene editing through the use of
CRISPR technology).
3
See Thom Patterson, Unproven Medical Technique Could Save Countless Lives, Billions of
Dollars, CNN (Oct. 30, 2015), http://www.cnn.com/2015/10/30/health/pioneers-crisprdna-genome-editing/ [http://perma.cc/Q7XC-3JWL] (describing the health and financial
benefits CRISPR could bring to our society).
4
See, e.g., Edward Lanphier et al., Don’t Edit the Human Germline, NATURE
http://www.nature.com/news/don-t-edit-the-human-germ-line-1.17111 (Mar. 12, 2015),
[htttp://perma.cc/MRW2-MHVW] (exemplifying one of many ethical concerns involving
CRISPR). The article discusses the most serious concerns involving permanent changes to
human DNA. Id.
5
See Staff Reporter, GENOMEWEB https://www.genomeweb.com/gene-silencinggeneediting/scientists-call-caution-use-crisprcas9-technology
[http://perma.cc/5X6R-V3RX]
(reporting the weighing tests scientists consider when acknowledging the benefits and
consequences associated with CRISPR). Scientists have called for transparency and
standardized benchmarking in an attempt to curb concerns of human germline modification.
1
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This Note aims to answer some of these questions by proposing new
legislation that could be passed by Congress to help facilitate further
research involving CRISPR, while also addressing many of the ethical
concerns that have many fearful for the future direction of biosciences. 6
Part II of this Note outlines the background behind CRISPR by first
briefly discussing the inception of CRISPR and how it is truly
revolutionary in comparison to the technologies that came before it.7 Part
II.B continues by explaining what CRISPR is, how it works, and the
potential benefits of CRISPR as well as the relevant ethical considerations.8
Part III analyzes the current law and balances the law with the current
scientific and ethical discussions going on regarding CRISPR. 9 Part III also
explains why new legislation is not only necessary to address these
problems, but also why legislation is the most effective and efficient way
of doing so as opposed to alternative proposals. 10 Part IV provides ethical
boundaries and funding considerations that should be met with this
legislation.11

Id. Human germline modification is the editing of genes of future generations of humans.
About Human Germline Editing, CTR. FOR GENETICS AND SOC. (July 9, 2015),
http://www.geneticsandsociety.org/article.php?id=8711 [http://perma.cc/BM5K-64HX].
“Human germline gene editing” or “human germline modification”
means deliberately changing the genes passed on to children and future
generations–in other words, creating genetically modified people.
Human germline modification has for many years been widely
considered off-limits, for both safety and social reasons. It is formally
prohibited in more than 40 countries.
Id.
6
See infra Part IV.A (proposing a piece of legislation to address multiple ethical and legal
concerns associated with CRISPR, while also attempting to facilitate further research).
7
See infra Part II.A (chronicling the advances in research that led to the discovery of
CRISPR in bacteria and developing it into a tool).
8
See infra Part II.B (discussing the revolutionary power of CRISPR and why it raises such
urgent ethical and legal issues).
9
See infra Part III (advocating for changes in the law, partially by repealing the DickeyWicker Amendment that no longer accurately serves its original purpose).
10
See infra Part III.B (explaining the unique advantages that naturally come with solving
legal issues through new legislation).
11
See infra Part IV (proposing a model act with narrowly tailored guidelines for directing
federal funding toward CRISPR research). This act aims to fund certain types of studies on
CRISPR with the goal of being an investment in public health. Id. This proposed act
proposes a repeal of the Dickey-Wicker Amendment, as discussed in Parts II and III. Id.
Next, the proposed act establishes a series of guidelines that specifically detail the types of
studies that are funded by this act. Id. Additionally, the proposal specifies the types of
research that are wholly prohibited, and what types of repercussions could follow if such a
guideline is violated. Id. After the proposal is fully laid out, Part IV will continue by
addressing a few anticipated reactions and arguments against this proposal. Id. These
counter-arguments provided will involve the scope of the proposal and differentiating
between the proposed act laid out below and recent developments in the law. Id.
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II. BACKGROUND
Gene editing is a practice that has been developing and has been
theorized over the past few decades.12 “What used to be science fiction”
has suddenly become a real part of modern science and medicine. 13 Part
II.A briefly traces the history of gene editing and its development up to
this point.14 Next, Part II.B discusses what CRISPR/Cas9 is, how it works,
and why it has changed the way we look at science and medicine. 15 Part
II.C touches on the ethical issues CRISPR raises and why these concerns
should be immediately addressed by scientists, ethicists, and lawmakers.16
Part II.D brings attention to the current legal issues that CRISPR is
encountering as the full potential of CRISPR technology is being
realized.17 A background on each of these subjects is necessary to consider
the legal and ethical landscape ahead of us, and how lawmakers can most
efficiently address these numerous issues. 18
A. Gene Editing and the Development of CRISPR
Gene editing can be traced back to studies in the 1980s that looked to
modify specific genes in mice.19 Shortly after that, gene-editing
technologies, such as TALENs, were developed as efficient ways to
modify an organism’s genes.20 The development of these technologies
quickly accelerated after scientists successfully mapped the human

12
See CRISPR Timeline, supra note 1 (tracing the theoretical discovery of a CRISPR system
back to 1993 or earlier).
13
See Jennifer Doudna, How CRISPR Lets Us Edit Our DNA, TED, at 11:55,
https://www.ted.com/talks/jennifer_doudna_we_can_now_edit_our_dna_but_let_s_do_i
t_wisely?language=en [https://perma.cc/ZGN2-2C4Z] (suggesting that this subject could
easily be seen as ridiculous because of its impossibility only a few years ago).
14
See infra Part II.A (setting up the revolutionary nature of CRISPR).
15
See infra Part II.B (explaining CRISPR in further detail to highlight why the technology
is so controversial).
16
See infra Part II.C (turning to the specific concerns scientists, ethicists, and lawmakers
alike have regarding proceeding with further research involving CRISPR).
17
See infra Part II.D (delving into issues raised by the Dickey-Wicker Amendment and
Sherley v. Sebelius in the United States District Court of Washington D.C.).
18
See infra Part IV (advocating for a remedy to these problems through new legislation).
19
See Jon Chestnut, Analyzing TALEN v. CRISPR, GENETIC ENG’G & BIOTECHNOLOGY
NEWS (Oct. 13, 2016), http://www.genengnews.com/gen-exclusives/analyzing-talen-vscrispr/77900759 [https://perma.cc/P83U-LYVX] (mentioning a brief description of early
gene-editing research in the 1980s conducted on mice).
20
See id. (explaining TALENs as an alternative gene-editing method that is highly
accurate, but lacks the “simplicity and versatility of CRISPR”). TALENs stands for
Transcription Activator-Like Effector Nucleases. Id. One clear advantage is that TALENs is
licensed for commercial use. Id. CRISPR is still in a bitter patent dispute, which maintains a
level of uncertainty with its availability for commercial use in the very-near future. Id.
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genome in 2003.21 But, it wasn’t until 2012 when Professor Jennifer
Doudna and her colleagues at the University of California, Berkeley
discovered a breakthrough technology now known as CRISPR/Cas9 (or
CRISPR) in bacteria.22
Before the development of CRISPR, the process of editing genes was
an arduous process that would cost thousands of dollars for each use and
could have taken weeks or months to achieve a desired result. 23 Even
then, the results lacked accuracy—which is a great concern in the business
of changing an organism’s genes.24 Now CRISPR has provided an
exponentially faster method of altering DNA. 25 Additionally, the cost of
a single use of the technology has been reduced to about $75 per use.26 On
top of the increased affordability and speed of the gene-editing
technology, CRISPR has improved accuracy of the desired result
tremendously.27
See Human Genome Project, NAT. INST. OF HEALTH, https://report.nih.gov/
nihfactsheets/ViewFactSheet.aspx?csid=45 [https://perma.cc/M7MG-86LF] (chronicling
the human genome project and what has resulted from the project’s completion). Notably,
over “1,800 disease genes” have been discovered. Id.
22
See Jinek et al., supra note 2, at 816–21 (presenting the discovery of the CRISPR system
in bacteria). The naturally occurring CRISPR system was discovered as a result of evolution
in bacteria. Id. It is the process by which bacteria fights off viruses, similarly to the way a
vaccine works in patients. Id. A bacteria cell is able to record or “take a snapshot” of the
virus DNA so that the next time the bacteria encounters a virus with that DNA, it will be
able to efficiently attack that virus through its recognition recorded by CRISPR. Id. This
Note references Jennifer Doudna as the discovering part of the CRISPR technology (as she
has been represented in the media), but this could be disputed. Broad Inst., Junior Party v.
The Regents of The University of Cal., Patent Interference No. 106,048 (P.T.A.B., Feb. 15,
2017). Doudna and her team lost the first stage of the CRISPR patent dispute in early 2017,
which will likely continue through several rounds of appeals. Id.
23
See generally Jim Yeadon, Pros and Cons of ZNFs, TALENs, and CRISPR/Cas, JACKSON LAB.
(Mar. 4, 2016), https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-andcons-of-znfs-talens-and-crispr-cas# [https://perma.cc/QK63-UB4D] (discussing Zinc
Finger Nucleases (ZFN or ZNF) and TALENs as alternatives to earlier gene-editing
technologies). While both technologies are still used and have their advantages, both have
been overshadowed by CRISPR’s abilities. Id.
24
See generally id. (describing how CRISPR is far more economically feasible and far more
accurate).
25
See id. (listing differences between CRISPR, TALENs, and ZNFs). See, e.g., Overview,
INTELLIA THERAPEUTICS (last visited Sept. 3, 2017), http://www.intelliatx.com/aboutus/overview/ [https://perma.cc/MV9G-6RH7] (describing the company as a “leading
genome editing company”). Intellia was founded by co-inventor of CRISPR, Jennifer
Doudna. Id. See also, Company Overview, EDITAS MEDICINE (last visited Sept. 3, 2017),
http://www.editasmedicine.com/company-overview
[https://perma.cc/6HJF-5NWJ]
(presenting itself as another “leading genome editing company”).
26
See generally Yeadon, supra note 23 (noting how previous gene-editing techniques could
take “2-3 years to complete and could cost up to $100,000”).
27
See generally Yeadon, supra note 23 (explaining CRISPR’s ability to target specific genes
to change or delete).
21
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B. How CRISPR Works and Why it is a Game-Changer
CRISPR’s revolutionary ability is derived from a naturally occurring
process in human immune systems, whereby proteins can recognize
foreign organisms such as viruses.28 The proteins then work with the
DNA to take a “snapshot” of this potentially harmful organism so that the
cell may recognize it again at a later time and know how to attack it,
thereby eliminating the virus from the body.29 Scientists have learned to
influence this process by using the Cas9 protein to first locate a specific
sequence in an organism’s DNA. 30 After the desired sequence is
identified, the protein is then able to “cut out” the selected sequence and
replace it with an entirely new DNA sequence.31 As a result, this changes
one of the organism’s natural traits.32
In the naturally occurring version of this process, DNA is altered to
build immunity to foreign and possibly harmful organisms like viruses.33
With CRISPR, the intentional alteration of DNA may come with a wide
range of goals.34 Some of these goals are more practical, while others are
28
See Jinek et al., supra note 2, at 816–21 (recounting the discovery which first occurred in
bacteria cells, where the bacteria cells use RNA to record a genetic “snapshot” of the virus in
order for the cell to better protect itself against future viral attacks).
29
See Doudna, supra note 13, at 00:33 (analogizing the CRISPR process to a human
immune system).
30
See Jinek et al., supra note 2, at 820 (explaining how scientists may harness this process
and manipulate it to target specific genes).
31
See Jinek et al., supra note 2, at 816 (illustrating how RNA strands are guided by the Cas9
protein to read and identify specific genes).
32
See Genes, MERRIAM-WEBSTER (last visited Sept. 3, 2017), http://www.merriamwebster.com/dictionary/gene [https://perma.cc/VZV4-HQTM] (providing a definition of
“gene” as a part of a cell that controls or influences the appearance, growth, etc. of a living
thing). A more specific definition provides:
A specific sequence of nucleotides in DNA or RNA that is located
usually on a chromosome and that is the functional unit of inheritance
controlling the transmission and expression of one or more traits by
specifying the structure of a particular polypeptide and especially a
protein or controlling the function of other genetic material.
Id. See also Traits, MERRIAM-WEBSTER (last visited Sept. 3, 2017), http://www.merriamwebster.com/dictionary/trait [https://perma.cc/DPX7-V5MR] (describing a trait as “a
quality that makes one person or thing different from another”).
33
See Jinek et al., supra note 2, at 820 (providing the conclusions reached by the study).
34
See Antonio Regalado, Engineering the Perfect Baby, MIT TECH. REV. (Mar. 5, 2015),
https://www.technologyreview.com/s/535661/engineering-the-perfect-baby/
[https://perma.cc/YLA7-SCYX] (providing the wide-ranging potential of CRISPR).
Purposes range from medical to cosmetic. Id. Some scientists aspire to bring back extinct
species, while others aim to cure diseases or solve world hunger. Id. While other uses may
have an impact on public health, such as using CRISPR on crops to combat world hunger or
to increase the health benefits of certain foods, those issues are outside the scope of this
discussion. Id. The use of CRISPR to combat diseases spread by animals is also outside the
scope of this Note. Id. Using CRISPR on viable human embryos that will eventually develop
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more theoretical for the time being (even though the technology’s ability
already exists).35 Of the more immediately practical uses, some scientists
see value in using CRISPR to alter crops in a variety of ways, such as
combatting world hunger, or climate change by developing food that can
grow in a changing climate, as well as herbicide resistant crops. 36 Using
CRISPR on animals also has potential value in a more narrow sense. 37
Altering the DNA of mosquitoes so that they are incapable of carrying the
West Nile or Zika viruses is an example that provides humans with
advantages in eradicating diseases. 38 However, the most popular
proposed use of CRISPR involves human application to treat and cure
various human ailments.39 The medical application of CRISPR is likely

into a person will not be permitted with this act. Id. The concerns involving cost of CRISPR
treatments are too skeptical at this point in time and the relevant problems are still not
entirely tangible. Id. Finally, theoretical uses including resurrecting extinct species will not
be discussed. Id. These exclusions are not intended to rule on the merits of those scientific
goals, but to restrict this act to aid the issues most immediately of concern to the American
public. Id. It is not out of the question for these excluded issues to still be addressed in this
act, but for the purpose of having a narrowly tailored goal, they will be regarded as outside
the scope of consideration. Id.
35
See generally Abumrad & Krulwich, http://www.radiolab.org/story/antibodies-part1-crispr/ [https://perma.cc/3JQA-EPJ2] (recounting an earlier conversation between one of
the hosts and an anonymous scientist familiar with CRISPR). While the scientific value of
changing a Golden Retriever into a Great Dane likely does not exist, scientists claim to
already have the power to do so with CRISPR. Id. Using DNA found from Wooly Mammoth
hair could be inserted into an elephant embryo and it could develop into a fully grown, living
Wooly Mammoth. Id.
36
See Maywa Montenegro, CRISPR is Coming to Agriculture–With Big Implications for Food,
Farmers, Consumers, and Nature, ENSIA (Jan. 28, 2016), http://ensia.com/voices/crispr-iscoming-to-agriculture-with-big-implications-for-food-farmers-consumers-and-nature/
[https://perma.cc/SD59-BSAR] (stating the intended uses of CRISPR in agriculture range
from “crop resistance to pests to livestock disease”). See also Alison Peck, The Failure of Federal
Biotechnology Regulation, 51 VAL. U. L. REV. 483, 510 (2017) (describing the use of CRISPR in
crops).
37
See generally id. (discussing various attempts made to address problems related to
livestock diseases and production).
38
See id. (explaining the highly controversial idea of using CRISPR to sterilize the roughly
thirty species of mosquitoes that carry malaria, effectively driving them to extinction). This
can be done by using CRISPR on viable mosquito embryos. Id. This type of change (as
opposed to a change to an adult mosquito) would be naturally passed down to that
mosquito’s offspring, thereby permanently changing the mosquito’s genome. Id. Issues
involving altering the DNA of viable human embryos and altering the human germline are
the primary ethical issues linked to CRISPR, both of which will be discussed later. See also
infra Part II.C (providing information on germline editing); infra Part III (discussing aspects
of the law and their effect on CRISPR).
39
See generally Patterson, supra note 3 (noting the specific plans to go after genes linked to
obesity and Alzheimer’s).
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the most immediate potential use of CRISPR, as scientists are already
beginning human trials on a small scale.40
Scientists and medical experts alike are thrilled with the prospect of
treating or even curing diseases such as Alzheimer’s, to other genetic
diseases from muscular dystrophy to rare forms of blindness. 41 The first
studies that research the human application of CRISPR are underway in
other countries, while the first clinical trial here in the United States was
approved by a federal ethics panel in June of 2016.42 However, the ethical
concerns involved with CRISPR are many in number and are the primary
reason why research has slowed for the time being. 43
C. Ethical Considerations Linked to CRISPR
Despite the possible benefits of curing many of the diseases that have
plagued humanity for centuries, many scientists, ethicists, and lawmakers
believe that we should seriously consider how far we are willing to go in
order to achieve such results.44 If humans have the power to alter the
40
See generally Patterson, supra note 3 (implying that CRISPR will not be raising extinct
species in the near-future). See also Emily Mullin, Gene Editing Study in Human Embryos Points
Toward Clinical Trials, MIT TECH. REV. (Aug. 2, 2017), https://www.technologyreview.com/
s/608482/gene-editing-study-in-human-embryos-points-toward-clinical-trials/
[https://perma.cc/TSU3-768T] (discussing one of the most recent studies using CRISPR).
41
See Megan Thielking, Using CRISPR to Edit Out Blindness, STAT (Jan. 27, 2016),
https://www.statnews.com/2016/01/27/crispr-gene-editing-blindness/
[https://perma.cc/682T-6JR9] (reporting on the ability to create retinal cells using CRISPR
and to transplant them into a patient experiencing blindness due to a genetic mutation).
42
See Sharon Begley, Federal Panel Approves First Use of CRISPR in Humans, STAT (June 21,
2016), https://www.statnews.com/2016/06/21/crispr-human-trials/ [https://perma.cc/
QW9Y-Q9KC] (discussing a proposed study that would use CRISPR to “alter immune cells
to attack three kinds of cancer”). The National Institutes of Health’s Recombinant DNA
Advisory Committee (RAC) approved the study unanimously. Id. The study will be the first
clinical trial in the United States and will test the safety of the human application of CRISPR.
Id. Studies such as this are precisely the type this proposed legislation aims to encourage
and make more common. See also Mullin, supra note 40 (discussing a groundbreaking study
involving human embryos); infra Part III.D (reflecting CRISPR’s progress through current
and proposed studies).
43
See generally Abumrad & Krulwich, supra note 35 (saying that the term moratorium is
perhaps too severe in light of remaining goals to continue CRISPR research). See also
Doudna, supra note 13 (asking for a temporary “moratorium” on the use of CRISPR in
embryos). Doudna cites to “recent precedent” for such a temporary moratorium, as
molecular cloning became possible in the late 1970s. Id.
44
See Genetically Engineered Human DNA: Hearing before the Subcomm. on Research and
Technology of the H. Comm. on Science, Space, and Technology, 114th Cong. (2015) (statement of
Jeffrey P. Kahn) http://congressional.proquest.com.ezproxy.valpo.edu/congressional/
result/congressional/pqpdocumentview?accountid=14811&groupid=95261&pgId=687815
76-d0a2-4cc3-90e2-5799ae98f525&rsId=1577698A153
[https://perma.cc/P6GR-V8PD]
(testifying to the importance of establishing an ethical framework for how to approach
CRISPR).
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DNA of their own species, what would keep them from using that ability
frivolously or to disadvantage certain classes of people?45 This does not
exclude Jennifer Doudna, CRISPR’s co-creator.46 She believes that
permanently altering the human germline is an irresponsible and
dangerous step to take at this point in time.47
This ethical concern largely involves the use of CRISPR on viable
human embryos.48 If changes are made to the DNA of a human embryo
that will eventually grow into a living person, those alterations are not
only permanent, but will be passed on to the individual’s offspring. 49 This
is what scientists call “editing the human germline.” 50 Editing the human
germline irreversibly changes the natural path of human evolution and
essentially puts humans in control of their own future, taking it out of
nature’s hands.51
See generally Anna Louise Sussman, Burden of Healthcare Costs Shifting to the Middle Class,
THE WALL STREET JOURNAL (Aug. 25, 2016), http://www.wsj.com/articles/burden-ofhealth-care-costs-moves-to-the-middle-class-1472166246 [https://perma.cc/KK94-H65H]
(discussing the general burdens of health care costs and how they are disproportionately
harming the middle class).
46
See Abumrad & Krulwich, supra note 35 (calling for a temporary moratorium on using
CRISPR). Jennifer Doudna states that CRISPR is not yet ready for human application,
primarily because of a lack of success in a Chinese study done on unviable human embryos.
Id.
47
See Abumrad & Krulwich, supra note 35 (noting specifically the permanent effect of
editing the human germline).
48
See generally Ewen Callaway, Second Chinese Team Reports Gene Editing in Human
Embryos, NATURE (Apr. 8, 2016), http://www.nature.com/news/second-chinese-teamreports-gene-editing-in-human-embryos-1.19718
[https://perma.cc/CQ3Y-9PQB]
(reporting on a Chinese study which used unviable human embryos). While the article notes
remaining controversy; in using unviable embryos, it clarifies that no viable embryos were
used, emphasizing what a wholly unethical step it could have been. Id.
49
See Patrick Skerrett, A Debate: Should We Edit the Human Germline?, STAT (Nov. 30, 2015),
https://www.statnews.com/2015/11/30/gene-editing-crispr-germline/
[https://perma.cc/T7YH-U2VT] (discussing the risks associated with editing the human
germline). See also Jeff Delviscio, NIH Director Francis Collins to Stay on, At Least for Now,
Under Trump, STAT (Jan. 19, 2017), https://www.statnews.com/2017/01/19/franciscollins-nih-donald-trump/ [https://perma.cc/Y5BG-5NMH].
President Trump has
retained Collins for now, but the director may not be kept on for a full term. Id.
50
See id. (describing germline editing). Francis Collins states that “medical research
should always seek to balance benefits and risks.” Id.
51
See Skerrett, supra note 49 (explaining the nature of germline editing). George Church
asks what we should consider improvements in the human germline. Id. This work can be
done through the use of gene drives. See also Brooke Borel, When Evolution Fights Back Against
Genetic Engineering, THE ATLANTIC (Sept. 12, 2016), https://www.theatlantic.com/science/
archive/2016/09/gene-drives/499574/ [https://perma.cc/DA8C-AU87]. The use of gene
drives is a process that is essentially a “forced succession” of a trait. Id. This process has
already been successfully executed on fruit flies in a lab setting. Id. However, scientists
disagree as to how a gene drive would play out in the wild, should it ever occur. Id. They
may be just as likely to destroy a species as they are to save or alter one. Id.
45
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Since the inception of in vitro fertilization (IVF), people have had the
ability to choose the sex of their child, as well as their eye or hair color. 52
However, CRISPR raises new issues in this respect. 53 The accuracy, ease
of use, and affordability of CRISPR leads many to wonder what would
prevent parents from increasing the intelligence of their child or making
them more physically gifted.54 Using CRISPR with the goals of changing
the appearance, strength, or intelligence of future generations is a major
concern of many.55 The idea of genetically engineered humans to this
degree still sounds like science fiction, but the issue caught the attention
of the MIT Technology Review enough to warrant a cover story in 2015 on
exactly this issue.56 While arguably speculative, the next logical concern
is the potentially increased costs of these types of procedures, which
would lead to only the higher economic classes having access,
disadvantaging the majority of Americans.57

52
See Emily Singer, Choosing Babies, MIT TECH. REV. (Mar. 1, 2007),
https://www.technologyreview.com/s/407398/choosing-babies/
[https://perma.cc/
76LY-JCGN] (reporting how parents frequently use in vitro fertilization to choose the sex of
their child).
53
See id. (speculating that parents may someday be choosing the IQ of their child). See
also Regalado, supra note 34 (discussing the present concern of CRISPR’s future ability to
control an embryo’s genes that control intelligence).
54
See Regalado, supra note 34 (explaining the numerous types of genetic alterations that
could be made to a child during the prenatal stages of development).
55
See id. (discussing the more theoretical, but scientifically possible future uses of CRISPR
which concern many scientists). These concerns include permanent changes to the human
genome. Id. There are also slippery slope arguments pertaining to somatic gene therapy.
See also Tony McGleenan, Human Gene Therapy and Slippery Slope Arguments, 21 J. OF MEDICAL
ETHICS, 350–55 (1995). Somatic gene therapy includes gene therapy where DNA changes are
not passed down to further generations. Id. These arguments could potentially be carried
over to germline editing discussions. Id. These arguments can be classified as logical
slippery slope arguments and rhetorical slippery slope arguments. Id. However, “with
unambiguous legislation logical slippery slope arguments have little or no force.” Id. These
arguments mostly become relevant when regulation is on the table. Id. When it comes to
rhetorical slippery slope arguments, the flaws can often be resolved with close analysis. Id.
This is because the rhetorical slippery slope arguments often present larger leaps in logic. Id.
56
See Regalado, supra note 34 (noting CRISPR’s capabilities rather than its current uses).
See also generally McGleenan, supra note 55 (inferring that this concern falls in line with a
logical slippery slope argument that the legalization of germ line editing could lead to
designer babies).
57
See generally David Warmflash, Gene Therapy 2.0: Will CRISPR Make Expensive Treatment
Accessible
to
All?,
GENETIC
LITERACY
PROJECT
(Aug.
16,
2016),
https://www.geneticliteracyproject.org/2016/08/16/gene-therapy-2-0-will-crispr-makeexpensive-treatment-accessible/ [https://perma.cc/HBE2-ZCTD] (noting current gene
therapy treatments to cost around $1,000,000).
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D. Legal Implications
The problems CRISPR is encountering in regards to federal funding
begin with The Dickey-Wicker Amendment, and therefore, this discussion
must logically begin there.58 Discussing what The Dickey-Wicker
Amendment was intended for, and how it has been interpreted, is critical
to understanding the problem and the appropriate remedy for CRISPR to
attain federal funding.59 Part II.D.1 discusses the ethical scope of the
Dickey-Wicker Amendment and its implications related to CRISPR.60
Next, Part II.D.2 discusses how Sherley v. Sebelius could affect CRISPR
going forward.61 Together, this legal and ethical background and analysis
will provide a sufficient basis for the introduction of new legislation. 62 The
ultimate goal of this section is to examine the original purposes of the
Dickey-Wicker Amendment and analyze the interpretations of the
The effects of the Dickey-Wicker
Dickey-Wicker Amendment.63
Amendment on the National Institutes of Health (NIH) have prevented
them from funding promising advances in science such as CRISPR. 64
1.

The Dickey-Wicker Amendment

In 1996 a bill that would become the “The Balanced Budget Down
Payment Act of 1996” was introduced in the U.S. House of
Representatives.65 The text of Section 128 of this bill would become known

See infra Part II.D.1 (discussing the Dickey-Wicker Amendment).
See infra Part II.D.2 (analyzing the Sherley v. Sebelius case).
60
See infra Part II.D.1 (examining the shifting ethical considerations associated with the
Dickey-Wicker Amendment). See also Part III.B (analyzing various proposals).
61
See infra Part II.D.2 (discussing the effect of Sherley v. Sebelius on CRISPR).
62
See infra Part III (proposing new legislation).
63
See infra Part II (discussing, generally, the implications of the Dickey-Wicker
Amendment).
64
See Francis S. Collins, Statement on NIH Funding of Research Using Gene-Editing
Technologies in Human Embryos, NATIONAL INSTITUTES OF HEALTH (Apr. 29, 2015),
https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nihfunding-research-using-gene-editing-technologies-human-embryos
[https://perma.cc/93FU-P8AJ] (exemplifying the impact of the Dickey-Wicker Amendment
in 2015). “Practically, there are multiple existing legislative and regulatory prohibitions
against this kind of work.” Id. “The Dickey-Wicker amendment prohibits the use of
appropriated funds for the creation of human embryos for research purposes or for research
in which human embryos are destroyed.” Id.
65
See The Balanced Budget Downpayment Act, Pub. L. No. 104–99, § 128, 110 Stat. 34
(1996) [hereinafter The Balanced Budget Downpayment Act] (providing original text of the
bill). The name of the amendment comes from the sponsors of the amendment,
Representative Jay Dickey of Arkansas’ 4th District and now-Senator Roger Wicker of
Mississippi’s 1st District. Id. This was one section of a larger appropriations bill pertaining
to the Departments of Interior, Labor, Health and Human Services, and Education. Id.
58
59
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as the Dickey-Wicker Amendment in subsequent budget acts.66
amendment states:

515
The

None of the funds made available by Public Law 104–91
may be used for—
(1) the creation of a human embryo or embryos for
research purposes; or
(2) research in which a human embryo or embryos are
destroyed, discarded, or knowingly subjected to risk of
injury or death greater than that allowed for research on
fetuses in utero under 45 CFR 46.208(a)(2) and 42 U.S.C.
289g(b).67
At the time, Congressional opposition described the amendment as
pro-life opposition to IVF.68 What is certain is that the Dickey-Wicker
Amendment arose out of concern over IVF.69 The language of the law
explicitly prohibits federal funding to be applied to research on human
embryos.70 This broad language does not discern between viable and
unviable embryos; it appears more as a blanket prohibition. 71

66
See id. (giving the language of The Dickey-Wicker Amendment as it appears in
subsequent budget acts). The amendment provides that:
(a) None of the funds made available in this act may be used for—(1)
the creation of a human embryo or embryos for research purposes;
or (2) research in which a human embryo or embryos are
destroyed, discarded, or knowingly subjected to risk of injury or
death greater than that allowed for research on fetuses in utero
under 45 CF.R. 46.208(a)(2) and section 498(b) of the Public Health
Service Act (42 U.S.C. 289g(b)). (b) For purposes of this section, the
term “human embryo or embryos” include any organism, not
protected as a human subject under 45 CF.R. 46 as of the date of the
enactment of this Act, that is derived by fertilization,
parthenogenesis, cloning, or any other means from one or more
human gametes or diploid cells.
Id.
67
See id. (providing the original language of the Dickey-Wicker Amendment).
68
See 142 Cong. Rec. 16,866 (1996) (debating the merits of conflicting amendments).
Whether the amendment was pro-life is debatable and irrelevant to this Note. Id.
69
See generally Ann A. Kiessling, The History of the Dickey-Wicker Amendment, BEDFORD
RESEARCH FOUNDATION (Aug. 24, 2010), http://archive.is/vjHtK [https://perma.cc/2B673V5G] (discussing the introduction of the Dickey-Wicker Amendment in light of the in vitro
fertilization and “test tube baby” debates).
70
See The Balanced Budget Downpayment Act, supra notes 65–66 (citing to the language
of the bill).
71
See id. (citing to the language of the bill).
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Of course, a bill restricting research in the field of biotechnology was
sure to become outdated relatively quickly.72 The amendment has had
unintended consequences as science has progressed over the past two
decades.73 The National Institutes of Health—the primary government
agency that awards research grants to medical studies across the
country—has identified this problem as one of the main reasons why they
will not fund gene-editing research.74 Attempts have been made to
eliminate or overturn the Dickey-Wicker Amendment, but those attempts
have been unsuccessful as they lack legislative action.75 An Executive
Order from President Obama in 2009 gave the NIH permission to fund
embryonic stem cell research.76 This order required the NIH to establish
new guidelines for how the organization approaches stem cell research. 77
Dickey-Wicker’s continuing impact can be felt to this day, as the
amendment has been included in every omnibus spending bill since the
Dickey-Wicker Amendment was enacted.78 Additionally, the United
States Court of Appeals weighed in on how the NIH should interpret the
Dickey-Wicker Amendment in Sherley v. Sebelius.79
72
See Sherley v. Sebelius, 689 F.3d 776, 779 (D.C. Cir. 2012) (describing the rapid advance
of stem cell research capabilities shortly after the initial enactment of the Dickey-Wicker
Amendment). At the time the Dickey-Wicker Amendment was drafted, germ line editing
was not scientifically feasible. See also McGleenan, supra note 55 (reflecting the progress of
gene editing in the 1990s). Cf. Sharon Begley, Scientists Solve CRISPR’s ‘Energizer Bunny’
Problem, STAT (Apr. 27, 2016), https://www.statnews.com/2016/04/27/crispr-energizerbunny-problem/ [https://perma.cc/L8A6-EE84] (exemplifying the rapid advances of
biotechnology, especially with CRISPR).
73
See Collins, supra note 64 (exemplifying the impact of the Dickey-Wicker Amendment
in 2015).
74
See Collins, supra note 64 (stating the National Institutes of Health stance on awarding
grants to gene-editing research with the Dickey-Wicker Amendment still in place).
75
See, e.g., Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (allowing the NIH
to conduct and fund research on human embryos to the extent of the law, but the extent of
the law is where the Dickey-Wicker Amendment begins).
76
See id. (addressing the issue of embryonic research as it pertains to the stem cell research
controversy).
77
See 74 Fed. Reg. 32,170 (July 7, 2009) (describing the guidelines). See also Sherley, 689
F.3d at 780 (discussing the new NIH guidelines as they apply to the Dickey-Wicker
Amendment in the facts of the case).
78
See, e.g., The Balanced Budget Downpayment Act, supra notes 65–66 (exemplifying the
continued presence of the amendment the 2015 budget).
79
See Sherley, 644 F.3d at 390 (discussing President Obama’s Executive Order and its effect
on the interpretation of the Dickey-Wicker Amendment). The Supreme Court discusses the
history of the Dickey-Wicker Amendment in more detail:
In 1996, when the Congress first passed Dickey–Wicker, scientists had
taken steps to isolate ESCs but had not yet been able to stabilize them
for research in the laboratory. The historical record suggests the
Congress passed the Amendment chiefly to preclude President Clinton
from acting upon an NIH report recommending federal funding for
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Sherley v. Sebelius & The National Institutes of Health

Sherley v. Sebelius arose out of dispute about NIH guidelines that were
mandated by an executive order from President Obama in 2009.80 Prior to
this proclamation, President Bush had also issued an executive order
permitting stem cell research in a very restricted manner.81 Scientific
advances in the years following the creation of the Dickey-Wicker
Amendment led to President Obama’s proclamation allowing the NIH to
support stem cell research “to the extent permitted by law.” 82 It is this
executive order that led to the dispute in Sherley.83 The guidelines
required in President Obama’s executive order provided stem cell
researchers with fewer restrictions in their work.84 Accordingly, the
appellant brought the action after its concerns went unaddressed during
the comment period.85
In the Sherley court’s analysis the interpretation of the term “research”
in the Dickey-Wicker Amendment was deemed ambiguous, which sided

Id.

research using embryos that had been created for the purpose of in vitro
fertilization. Dickey–Wicker became directly relevant to ESCs only in
1998, when researchers at the University of Wisconsin succeeded in
generating a stable line of ESCs, which they made available to
investigators who might apply for NIH funding.
For that reason, on January 15, 1999, the General Counsel of the
Department of Health and Human Services issued a memorandum
addressing whether Dickey–Wicker permits federal funding of research
using ESCs that had been derived before the funded project began; she
concluded such funding is permissible because ESCs are not “embryos.”
After notice and comment, the NIH issued funding guidelines
consistent with this opinion, but the NIH did not fund any ESC research
project while President Clinton was in office.

See id. at 779–80 (discussing executive orders issued by President George W. Bush and
President Obama). See also Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009)
(providing the original language of the executive order).
81
See Sherley, 644 F.3d at 779–80 (giving a brief background that led to the case at bar). See
also Proclamation No. 13,435, 72 Fed. Reg. 34,591 (June 27, 2007) (showing the scope of
President Bush’s executive order).
82
See Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (quoting the language of
the 2009 executive order).
83
See Sherley, 644 F.3d at 779–80 (discussing the background of the case).
84
See id. at 780 (citing to the executive order). The guidelines state the following:
Embryonic stem cell research project may receive NIH funding as long
as it utilizes cells from lines (1) created by in vitro fertilization for
reproductive purposes, (2) no longer needed for that purpose, and (3)
voluntarily donated by the individuals who owned them—even if that
line was derived after 2001).
Id.
85
See id. (discussing the original cause of action in the case).
80
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with the NIH’s interpretation. 86 By applying Chevron deference to the
NIH’s interpretation of the Dickey-Wicker Amendment, the court held
that it was reasonable to interpret the “term ‘research’ as a discrete project
rather than an extended process.” 87 As a result of this decision, the
destruction of embryos as part of the embryonic stem cell derivation
process was not a part of the funded research project, and therefore no
violation of the Dickey-Wicker Amendment existed.88 Additionally, the
court saw these enacted guidelines allowing for the funding of stem cell
research as following the triggering executive order.89 However, this
funding of stem cell research would not have been possible without the
two executive orders mentioned above, which specifically endorse stem
cell research to different extents. 90
86
See id. at 783 (applying the Chevron deference). The appellants in this case were
scientists objecting to the funding of any kind of stem cell research. Id. Specifically, the
group was opposed to the guidelines set out in President Obama’s executive order allowing
stem cell research to the extent allowed by law. Id. The appellants sought an injunction
against the NIH to halt the funding of any embryonic stem cell research despite President
Bush’s executive order allowing such funding for ten years. Id. The appellants’ argument
raised three main issues. Id. First, that the guidelines being implemented violated the
language of the Dickey-Wicker Amendment prohibiting funding for “research in which a
human embryo or embryos are destroyed.” Id. Second, that in the alternative, the guidelines
violate the language prohibiting research where human embryos are “subjected to risk of
injury or death greater than that allowed for research on fetuses in utero.” Id. Finally,
appellants argued that the failure to respond to objecting comments during the regulation’s
comment period. Id. The Court discounted all three arguments by applying Chevron
deference to the NIH’s interpretation of the executive order, and that the NIH has no duty
to respond to objections before the regulation is enacted. Id.
87
See Sherley, 689 F.3d at 783 (explaining how the NIH made a reasonable interpretation
of the term “research” as ambiguous); Chevron, U.S.A., Inc. v. Natural Resources Defense
Council, Inc., 467 U.S. 837, 865 (1984). Further, Justice Stevens states:
An agency to which Congress has delegated policy-making
responsibilities may, within the limits of that delegation, properly rely
upon the incumbent administration’s views of wise policy to inform its
judgments. While agencies are not directly accountable to the people,
the Chief Executive is, and it is entirely appropriate for this political
branch of government to make such policy choices—resolving the
competing interests which Congress itself either inadvertently did not
resolve, or intentionally left to be resolved by the agency.
Id. See Sherley, 689 F.3d at 785–87 (plurality opinion) (discussing how the concurring opinion
disagrees with the applicability of Chevron deference to executive orders). Judge Henderson
believes that it only applies to legislative material coming from Congress. Id. Chevron
deference provides administrative agencies the ability to resolve ambiguity in the language
of a law. Id.
88
See Sherley, 689 F.3d at 783–84 (explaining how the funded research projects did not
destroy human embryos or subject them to risk).
89
See id. at 785 (addressing the failure to reply to comments during the set time period
while the proposed change is made public).
90
See generally Consolidated Appropriations Act of 1996, Pub. L. No. 104-99, 110 Stat. 26,
34 (providing the language of the Dickey-Wicker Amendment preventing this type of
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Applicability to CRISPR

At this time, there is no such executive order or legislation that
specifically allows for the federal funding of research related to CRISPR. 91
As a result, the Dickey-Wicker Amendment still bars the NIH from
becoming involved with CRISPR. 92 In Sherley, executive orders react to
the progress of science.93 What is also evident is that these executive
orders were necessary to bypass the Dickey-Wicker Amendment.94 Since
the discovery of the CRISPR technology in 2012, no such executive orders
or legislation have been enacted relating to CRISPR.95 However, some
pieces of proposed legislation have come forward in 2017.96
Twenty years ago, long before the conception of CRISPR, lawmakers
recognized the problems involved with banning federal funding of stem
cell research.97 In 1996, there was support for the “Lowey Amendment,”
which would have overturned the Dickey-Wicker Amendment and
restored the federal government’s ability to fund embryonic stem cell
research.98 This amendment would have served as an appropriations bill
“rider,” rather than an independent bill.99 Ultimately, the arguments in
research). The court’s application of Chevron and the two executive orders gave the NIH
freedom to fund stem cell research. See also Sherley, 644 F.3d at 390. CRISPR lacks such an
executive order or legislation permitting federal funds to go towards CRISPR research
specifically. Cf. id. But The Dickey-Wicker Amendment is still good law. Id.
91
See Chestnut, supra note 19 (discussing the Dickey-Wicker Amendment’s bar on federal
funds going toward germ line editing).
92
See id. (implying the need for a new law allowing for the allocation of federal funds for
CRISPR research).
93
See Sherley, 644 F.3d at 390 (discussing the purpose of the two executive orders).
94
See Proclamation No. 13,435, supra note 82 (addressing recent advances in stem cell
research that had occurred shortly after the Dickey-Wicker Amendment was first enacted).
See also Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (reacting to further
progress in stem cell research).
95
See generally Collins, supra note 64 (illustrating the need for changes in the law).
96
See e.g., H.R. 2921, 114th Cong. (2015) (exemplifying proposed legislation that intended
to intensify stem cell research in the interest of possible clinical benefits). This bill exemplifies
recent attempts to facilitate genetic research. Id. But see H.R. 5269, 114th Cong. (2016)
(exemplifying the intensity of opposition to genetic research). This bill would intend to
nationally criminalize the destruction of a human embryos through in vitro fertilization or
other purposes. Id.
97
See 142 Cong. Rec. 16,864, 16,869 (1996) (stating the potential scientific benefits from IVF
and stem cell research known at the time). Representative Lowey mentions the potential for
finding treatments or cures for various types of cancer and other diseases. Id. Speakers
arguing for the adoption of the amendment also discuss their general intent to repeal the
Dickey-Wicker Amendment. Id.
98
See id. (debating whether the federal government should fund research on human
embryos).
99
See id. (describing the Lowey Amendment as a replacement for the Dickey-Wicker
Amendment, which did not come to fruition).
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opposition to the Lowey Amendment won out, especially the repeated
argument that taxpayer dollars should not go to the destruction of human
embryos.100
E. Current Landscape: Developing Legal and Ethical Issues
To paint a picture of where we stand with CRISPR now and what the
road looks like going forward, three primary issues should be
addressed.101 First, what type of funds are coming to CRISPR, and who
controls that money?102 Second, with the Dickey-Wicker Amendment still
in place, what are the ethical ramifications of that law today? 103 Finally,
with the recent amendments to NIH guidelines, how does it affect CRISPR
moving forward?104
Companies working with CRISPR have arisen in recent years that
either receive private funding, are publicly traded, or both. 105 This may
lead some to believe that the issue of funding is resolved and that private
funding is all that is necessary.106 However, institutions receiving only
private funding rather than government grants have fewer restrictions
and regulations to abide by.107 This is especially problematic with a highly
100
See id. (stating the argument from then-Representative Coburn that life at such an early
stage should not be destroyed). The arguments in support continually reiterate that the
nature of the research to be funded would not destroy any embryos. Id.
101
See infra Part II.E (providing information on the current outlook for CRISPR relating to
sources of funding, ethical concerns related to the Dickey-Wicker Amendment, and recent
updates to the National Institutes of Health guidelines).
102
See infra Part II.E (discussing the relevance of public and private funding in relation to
research on CRISPR).
103
See infra Part II.E (explaining current concerns about the Dickey-Wicker Amendment).
104
See infra Part II.E (reporting recent changes to the NIH guidelines which open the door
for CRISPR research).
105
See The Intellia Therapeutics IPO—Editas vs. Intellia, NANALYZE (Apr. 18, 2016),
http://www.nanalyze.com/2016/04/the-intellia-therapeutics-ipo-editas-vs-intellia/
[https://perma.cc/5SS9-UKBT] (discussing the initial public offerings (IPO) of Editas
Medicine and Intellia Therapeutics). These two companies debuted their IPOs during the
Spring of 2016 and recognize themselves as the future of gene-editing research. Id. After
initially taking in nearly $150 million combined for their IPOs, the stocks have halted in
growth. Id. This is likely due to the current patent litigation for CRISPR. Cf. id.
106
See generally id. (inferring that government funding could be seen as unnecessary in
light of the hundreds of millions of dollars that companies have been raising and receiving
from investors).
107
See Anna Zaret, Editing Embryos: Considering Restrictions on Genetically Engineered
Humans, 67 HASTINGS L.J. 1805, 1828–29 (2016) (proposing regulations on gene editing). The
author similarly proposes that laws such as the Dickey-Wicker Amendment prevent proper
regulation of gene-editing technologies. Id. However, the author stresses the need for a
committee to consider the ethical issues relating to different pieces of proposed legislation
as well as a commissioned federal entity that would perform similar functions in facilitating
gene-editing research. Id. Zaret’s proposal is similar in purpose to this Note, but focuses far
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controversial technology like CRISPR, which many claim needs
government oversight.108 With the Dickey-Wicker Amendment still in
place, proper oversight and regulation cannot be implemented.109 Ethical
guidelines on how research funds may be used are likely to be less
stringent, because federal funding is not being provided.110
At the peak of its relevancy, the Dickey-Wicker Amendment
attempted to halt the cutting-edge, but ethically debatable, science of stem
cell research.111 At this time in the mid 1990s, IVF was still controversial,
and little was known about stem cell research, and the potential benefits
of curing diseases were quite speculative.112 Twenty years later, these
prospects are much more tangible. 113 Not only are these benefits being
realized in lab settings, but the ethical discussions have shifted due to a
greater understanding of the science. 114 The primary ethical concerns
associated with CRISPR are no longer the destruction of embryos, but
instead what changes could eventually be made to human embryos. 115
This shift not only signals that new issues must be addressed in the
coming years, but also that the concerns addressed in the Dickey-Wicker
Amendment are becoming increasingly irrelevant. 116 Yet the law still
exists and still bars federal funding for research that has advanced

less on what institutions or government bodies may be required to address specific
legislation, but rather a specific ethical framework itself that will be discussed below. Id.
108
See Genetically Engineered Human DNA: Hearing before the Subcomm. on Research and
Technology of the H. Comm. on Science, Space, and Technology, 114th Cong. (2015) (statement of
Jeffrey P. Kahn, Professor of Bioethics and Public Policy; Deputy Director for Policy and
Administration, Berman Institute of Bioethics, Johns Hopkins University) (discussing
current ethical frameworks in place, current ethical issues, and policy involving CRISPR and
gene editing research).
109
See Zaret, supra note 107 (discussing regulation and the Dickey-Wicker Amendment).
110
See Collins, supra note 64 (explaining the negative implications of the Dickey-Wicker
Amendment on CRISPR research).
111
See 142 Cong. Rec. 16,864 (1996) (arguing the merits of the Dickey-Wicker Amendment
against the alternative Lowey Amendment).
112
See generally Sherley, 689 F.3d at 779 (noting the state of stem cell research in the mid
1990s). “At the time of the adoption of the first Dickey-Wicker rider, scientists had not yet
isolated embryonic stem cells (ESC), and the original enactment was apparently directed at
another type of research performed on human embryos in the field of in vitro fertilization.”
Id.
113
See Susan Noakes, CRISPR Gene Editing Heads to Human Trial as Cancer Treatment, CBC
NEWS (June 24, 2016), http://www.cbc.ca/news/health/human-trial-crispr-1.3651755
[https://perma.cc/UXB9-Z2RT] (discussing approval by an NIH review board). Even
though the clinical trial was approved, the study is privately funded by billionaire Sean
Parker’s cancer foundation. Id.
114
See id. (expressing the promise of CRISPR to treat or cure diseases in the near future).
115
See Regaledo, supra note 34 (acknowledging the power and capabilities of CRISPR).
116
See generally Consolidated Appropriations Act of 2015, Pub. L. No. 114-113, 129 Stat.
2242, 2283 (citing to the provisions of the Dickey-Wicker Amendment).

Produced by The Berkeley Electronic Press, 2018

Valparaiso University Law Review, Vol. 52, No. 3 [2018], Art. 3

522

VALPARAISO UNIVERSITY LAW REVIEW

[Vol. 52

dramatically in recent years.117 The Dickey-Wicker Amendment’s likely
unintended consequences are still ringing more than two decades later,
and its language is outdated to a point of concern for the medical and
scientific communities.118
Rapidly-developing science may lead to rapidly-developing policy,
and the NIH is no exception to this. 119 In 2016, the NIH updated their
guidelines to accommodate advancing research for CRISPR. 120 In the
same year, the NIH’s ethics panel approved a study involving the use of
CRISPR in an attempt to cure a rare form of blindness. 121 As of summer
2016, no research institution has come forward to offer a home to this
study and no start date had been announced.122 But new studies involving
CRISPR are reported on at an increasingly higher rate. 123 The NIH’s
willingness to adapt to CRISPR is an encouraging sign, and a bump in
investment of CRISPR may be on the horizon.124
The House and Senate passed the 21st Century Cures Act, in late
November and early December of 2016.125 This Act is a major bipartisan
effort to fund and overhaul different aspects of the healthcare industry. 126
Parts of this bill encourage the investment in cancer research generally,
and also provide enormous funding to the NIH.127 Some of these funds
may theoretically find their way to CRISPR research, but it may be some

117
See generally Collins, supra note 64 (acknowledging the problems still in place caused by
the Dickey-Wicker Amendment).
118
See id. (reiterating the concerns from the NIH director).
119
See, e.g., id. (providing the NIH’s original stance on CRISPR).
120
See Emerging Biotechnologies and the Role of the NIH RAC, NATIONAL INSTITUTES OF
HEALTH (June 16, 2016), http://osp.od.nih.gov/under-the-poliscope/2016/06/emergingbiotechnologies-and-role-nih-rac [https://perma.cc/NWF7-UXXF] (stating that the NIH
would alter its grant guidelines in light of CRISPR developments).
121
See Begley, supra note 42 (outlining the basic plan of the study).
122
See Doudna, supra note 13, at 11:17 (calling for a temporary moratorium on embryonic
CRISPR research). See also Begley, supra note 42 (reporting the proposal put forward by
researchers at the University of Pennsylvania). Cf. Jacob Sherkow, Is CRISPR Patent Dispute
Hurting Scientific Progress?, GENETIC LITERACY PROJECT (Apr. 19, 2016),
https://www.geneticliteracyproject.org/2016/04/19/crispr-patent-dispute-hurtingscientific-progress/ [https://perma.cc/5BWA-W66U] (discussing the CRISPR patent
battle). Research proposals have slowed and less research could take place before the
conclusion of CRISPR’s patent dispute. Id.
123
Cf. Begley, supra note 42 (approving research aiming to cure genetic diseases).
124
See generally id. (reporting on the NIH’s approval of a study using CRISPR). Cf.
Sherkow, supra note 122 (discussing the competing gene-editing companies).
125
See Sherkow, supra note 122 (stating the bill’s history). After three years of debate, both
houses passed the bill with overwhelming support. Id.
126
See id. (discussing the act’s bipartisan support).
127
See id. (stating the act’s inclusion of Vice President Biden’s “Moonshot”—an ambitious
aim to cure cancer).
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time before the direction of these new funds are realized. 128 President
Obama signed this act into law in December 2016.129 As explained below,
new legislation should be introduced to address these numerous issues. 130
However, the more pertinent question is what approach is most
appropriate to exploit the CRISPR technology and with what level of
caution should our society approach it? 131
III. ANALYSIS
The co-inventor of CRISPR, Jennifer Doudna, has called for a
worldwide “conversation” on how we should address the relevant ethical
issues.132 Knowing what we do about CRISPR and its potential, as well as
the law and policy surrounding gene editing, how our society addresses
the relevant issues becomes the pressing question. 133 Part III will attempt
to accomplish two goals.134 First, Part III.A synthesizes the present issue
that CRISPR raises in the United States.135 Second, Part III.B advocates for
the best method to address these issues. 136 The best way to remedy these
issues is new legislation that will not only repeal past law that inhibits
genetic research, but will also direct where federal funding for CRISPR
research will go.137
The Dickey-Wicker Amendment, which continues to be included in
each year’s consolidated appropriations act, has led to some unintended
consequences due to advances in genetics over the past two decades. 138
After some scientific advances with stem cell research, an executive order
128
See id. (discussing how the act will take years to implement because the bill includes
few deadlines and because it is over 1,000 pages long, among other reasons).
129
See Associated Press, Obama Signs 21st Century Cures Act into Law, (Dec. 13, 2016),
https://www.statnews.com/2016/12/13/21st-century-cures-obama-signs/
[https://perma.cc/C53E-2SGJ] (reflecting the quick passage of the act and subsequently
being signed into law by President Obama).
130
See infra Part III (calling for the introduction of a new federal legislation).
131
See infra Part III (discussing various approaches to handling CRISPR’s ethical concerns
through legislative and administrative means).
132
See generally Doudna, supra note 13, at 11:17 (citing Jennifer Doudna on her position on
a temporary halt to CRISPR’s use on embryos). See also Abumrad & Krulwich, supra note 35
(reiterating her stance on careful thought before proceeding with the editing of embryos).
133
See infra Part III (balancing concerns with the benefits to our society of attempting to
cure various genetic diseases).
134
See infra Part III (addressing the ethical problems we face with CRISPR and how we
may overcome such problems).
135
See infra Part III.A (discussing the problem presented).
136
See infra Part III.B (advocating for a particular solution).
137
See infra Part III.B (detailing a solution through new legislation that can repeal old law
while also directing research funds through ethical concerns).
138
See Consolidated Appropriations Act, supra note 78 (citing to the Consolidated
Appropriations Act of 2015, which includes the Dickey-Wicker Amendment).
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from President Bush adapted the law to the science.139 Two years later, an
executive order from President Obama similarly expanded the NIH’s
ability to fund stem cell research to the extent of the law.140 On top of these
two executive orders, the Sherley v. Sebelius court found that some
language of the Dickey-Wicker Amendment was ambiguous.141 With a
shift on the Supreme Court in 2017, it is unclear how such an
interpretation might change, if at all.142 Only a few cases exist that could
indicate Justice Gorsuch’s stance on a CRISPR issue relating to NIH

139
See Sherley, 689 F.3d at 780 (citing to President George W. Bush’s 2007 executive order
allowing for limited stem cell research).
140
See id. (providing the language of President Obama’s 2009 executive order).
141
See 689 F.3d at 780 (finding the word “research” to be ambiguous). Currently, no case
law exists on the issues of ethics, regulation, or funding for CRISPR. Id. The only case law
relating to CRISPR at this early stage of development has been related to the CRISPR patent
dispute. See also Junior Party, No. 106,048 (referring to the case between the University of
California and the Broad Institute). This case covered the first patent dispute involving
CRISPR. Id. Jennifer Doudna’s team at the University of California at Berkeley published
their now-famous CRISPR study in 2012, which described the use of CRISPR in bacteria and
the potential use of it in multicellular organisms. Id. Subsequently, the Broad Institute in
Massachusetts published a study confirming CRISPR’s capabilities in multicellular
organisms. Id. The California team submitted a non-expedited patent request before the
Broad Institute; however, The Broad Institute’s patent request was expedited and approved.
Id. As a result, the California team’s patent was reviewed later and caused a patent
interference, despite its earlier submission. Id. The court ruled that the California patent
partially infringed the Broad Institute’s patent and that the California patent was restricted
to technology relating only to CRISPR’s use in bacteria. Id. The ruling is thought by many
to be a major blow to the California team in what is likely an emerging multi-billion-dollar
industry. Id. Deborah Netburn, UC Berkeley Suffers Big Loss in CRISPR Patent Fight: What's
Next for the Powerful Gene-Editing Technology?, LOS ANGELES TIMES (Feb. 15, 2017),
http://www.latimes.com/science/sciencenow/la-sci-sn-crispr-patent-decision-20170215story.html [https://perma.cc/BGG4-KPLL] (showing the likelihood of this case to go
through multiple appeals before the dispute is completely resolved, which could likely take
years).
142
See Harry Enten & Oliver Roeder, Trump Picks Neil Gorsuch, A Scalia Clone, For The
Supreme Court, FIVETHIRTYEIGHT (Jan 31, 2017), http://fivethirtyeight.com/features/neilgorsuch-supreme-court-trump/ [https://perma.cc/L72F-U5RA] (stating Judge Gorsuch’s
“likelihood to invoke originalism in his opinions”). See also Pino v. United States, 507 F.3d
1233, 1238 (10th Cir. 2007) (certifying the question as to whether the Oklahoma Supreme
Court should hear an appeal on wrongful death of an unviable fetus). Judge Neil Gorsuch
wrote the opinion certifying the question for the state court. Id. This case presented the
question of whether a physician could be sued for wrongful death of a fetus that was
unviable before medical treatment had been administered to the carrying mother. Id.
Gorsuch stated that the question was “precisely the sort that calls for us to seek authoritative
guidance of the state supreme court.” Id. While this case only certified a question and did
not decide the issue at hand, this case may loosely indicate where Gorsuch stands in similar
cases that involve unviable embryos. See generally id. (providing the most relevant opinion
written by Gorsuch).
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guidelines.143 This would indicate that a solution may be necessary that
does not rely on whatever the current makeup of the Supreme Court is.144
Former Chief Justice Burger once said the following: “[t]he law does not
search out as do science and medicine; it reacts to social needs and
demands.”145 The law has reacted to the science on this issue before, now
it must be done again in a more conclusive manner. 146
Ethicists and scientists alike agree that the possibility of permanently
editing the human germline (which would involve editing genes of viable
human embryos) would be a dangerous and irreversible step for
science.147 This is not to say that the issue could never be revisited at some
point down the road.148 But the lack of understanding and experience we
have for this powerful tool creates too many uncertainties and risks.149
A. The Problem
Part III.A discusses the Dickey-Wicker Amendment and why the ban
on federal funding for embryonic research should be struck. 150 This
section also argues that law should be eliminated in order to make way
for more modern legislation that properly addresses CRISPR’s ethical
concerns.151 Clinical trials are underway using alternative gene-editing
tools.152 In China, four clinical trials involving CRISPR have been
announced and a study on human embryos has been conducted in the
143
See Pino, 507 F.3d at 1238 (allowing the review of a wrongful death claim relating to an
unviable fetus).
144
See Enten & Roeder, supra note 142 (discussing Justice Gorsuch’s time on the 10th
Circuit Court of Appeals in Denver and what can be drawn from his opinions).
145
George P. Smith, II, Accessing Genomic Information or Safeguarding Genetic Privacy, 9 J.L.
& Health 121, 133 (1994–1995) (quoting former Chief Justice of the United States Supreme
Court Warren Burger).
146
See infra Part IV (discussing the author’s proposal to fund and regulate CRISPR using
the relevant ethical concerns as a guide).
147
See, e.g., id. (exemplifying one leading argument to halt such research).
148
See Regalado, supra note 34 (saying that if were are to attempt to permanently remove
disease-causing genes from the human germline, editing embryos is the only known way of
doing so).
149
See, e.g., Begley, supra note 42 (reflecting the continuing improvement to CRISPR that
need to be made without having risk of inaccurate genetic alterations to patients).
150
See infra Part III.A (arguing that the Dickey-Wicker Amendment bans what is now safe
and ethical work and is too broad for what more modern ethical concerns are).
151
See infra Part III.A (setting out reasons for why the Dickey-Wicker Amendment is
inadequate). See also infra Part III.B (discussing various approaches to replacing the DickeyWicker Amendment).
152
See, e.g., Hultquist et al., A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies
of HIV-Host Interactions in Primary Human T Cells, CELL PRESS (2016),
http://www.sciencedirect.com/science/article/pii/S2211124716313365
[https://perma.cc/94P5-GS2U] (summarizing a clinical trial using Zinc Finger Nucleases
rather than CRISPR).
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United States.153 In the United States, scientists are successfully editing
human cell traits on a seemingly weekly basis in the lab. 154 All signs
suggest that it is only a matter of time before a treatment for one condition
or another is discovered.155 Whether that occurs in the next year or further
down the line, the United States should position itself to take advantage
of such a discovery.156
One reason this could be difficult is the Dickey-Wicker Amendment,
the bill rider that prevents the alteration of a human embryo regardless of
viability.157 This amendment needs to be altered or better yet eliminated
and replaced to accommodate further research using CRISPR. 158 Some of
the greatest potential from CRISPR comes from studies that involve
human embryos; however, when a law that makes such an act illegal,
problems predictably arise.159 Studies on unviable human embryos are
accepted among ethicists on a larger scale.160

153
See NATIONAL INSTITUTES OF HEALTH, ClinicalTrials.gov, https://clinicaltrials.gov/
ct2/results?term=crispr [http://perma.cc/DF5Z-MUXH] (providing basic details about the
four planned clinical trials in China). See also Mullin, supra note 40 (reflecting the rapid
progress of CRISPR research to the stages of studying it with human embryos).
154
See, e.g., Sharon Begley, CRISPR Identifies Genes that Might be Targeted to Hobble HIV
Infection, STAT (Oct. 25, 2016), https://www.statnews.com/2016/10/25/crispr-identifieshiv-genes/ [https://perma.cc/FZ5E-AWTS] (exemplifying research that has been
conducted on the HIV virus as progress that has already occurred in early CRISPR studies).
155
See generally Nanette Byrnes, A Big Bet That Gene Editing Will Cure Human Disease, MIT
TECH. REV. (July 25, 2016), https://www.technologyreview.com/s/601846/a-big-bet-thatgene-editing-will-cure-human-disease/ [https://perma.cc/9JJP-XZXY]
(stating
the
confidence from newly-public Editas Medicine about their planned research with CRISPR
and that the results will not disappoint).
156
See generally id. (reiterating the confidence within Editas). However, the technology to
specifically attack many of these genetic diseases is still being developed. Id.
157
See, e.g., The Balanced Budget Downpayment Act of 1996, supra notes 65–66
(exemplifying the language of the Dickey-Wicker Amendment in 2015’s Consolidated
Appropriations Act).
158
See generally id. (prohibiting harm to human embryos).
159
See generally The Guardian’s View on Human Genome Editing: Find, Replace – and Cure, THE
GUARDIAN (Sept. 2, 2015), https://www.theguardian.com/commentisfree/2015/sep/02/
the-guardian-view-on-human-genome-editing-find-replace-and-cure [https://perma.cc/
SZ5R-WX2N] (speaking to the benefits of permanently eliminating genetic mutations that
cause diseases). “Editing human embryos is categorically different to editing organs and
other tissues. Genetic changes made to an embryo go on to affect all the cells in the adult.”
Id. “That includes their sperm or eggs, so the changes are passed on to their children and all
future generations.” Id.
160
See generally Rob Stein, Breaking Taboo, Swedish Scientist Seeks to Edit DNA of Healthy
Human Embryos, NPR (Sept. 22, 2016), http://www.npr.org/sections/health-shots/
2016/09/22/494591738/breaking-taboo-swedish-scientist-seeks-to-edit-dna-of-healthyhuman-embryos [https://perma.cc/8MUG-QSDF] (recognizing the value of learning more
about embryo development).
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The Dickey-Wicker Amendment should be replaced because it no
longer serves its original purpose. 161 The law was intended to protect
prenatal life at a time when in vitro fertilization research was progressing
as a promising science itself.162 But, when a 20-year-old law infringes on
further scientific research due to its broad language, changes are in
order.163 While the NIH may have found a way around the amendment
by approving a study, research that involves unviable human embryos is
still legally dicey.164 This is because research on viable human embryos is
still considered to be a dangerous road to go down, and research involving
unviable embryos has reached a larger consensus of being permissible. 165
The Dickey-Wicker Amendment is still an imposing figure to those who
aim to advance research in this area.166 This is because the Dickey-Wicker
Amendment was directed toward concerns about the ethical nature of
IVF, which has proven to be a safe, and now-common procedure.167 This
See generally Megan Kearl, Dickey-Wicker Amendment, 1996, THE EMBRYO PROJECT
ENCYCLOPEDIA
(Aug.
27,
2010),
https://embryo.asu.edu/pages/dickey-wickeramendment-1996 [https://perma.cc/A73E-EWDB] (noting the amendment’s creation in
response to a push for embryonic research in light of in vitro fertilization). The DickeyWicker Amendment may have passed through Congress quickly because it was attached to
an appropriations bill and the legislature had recently “come off two government
shutdowns.” Id. See also Christopher Ingraham, Congressional Deadlock Has Doubled Since the
1950s, WASH. P. (May 28, 2014), https://www.washingtonpost.com/news/wonk/wp/
2014/05/28/congressional-gridlock-has-doubled-since-the-1950s/
[https://perma.cc/
G24Y-6H8Y] (tracing the percentage of issues left unlegislated in a given year). “In 1947–
1948, fewer than thirty percent of issues were left unlegislated.” Id. “In 2011–2012, seventyone percent of issues were unlegislated.” Id.
162
See generally id. (determining later that stem cell research was not blocked by this
amendment because it was sufficiently different from what the amendment banned).
163
See generally Phillip K. Howard, The Crippling Hold of Old Law, THE WALL STREET
JOURNAL (Apr. 1, 2016), http://www.wsj.com/articles/the-crippling-hold-of-old-law1459536718 [http://perma.cc/QCC3-JEMZ] (citing to a problem of “mountains of old
statutes and regulations” as one reason why government has become so slow and clunky).
164
See Begley, supra note 42 (stating that the NIH’s ethics committee approved a clinical
trial after altering their grant guidelines, although the study has not yet been approved by
the FDA).
165
See Jad Abumrad & Robert Krulwich, The Primitive Streak, RADIOLAB (Sept. 23, 2016),
http://www.radiolab.org/story/primitive-streak/
[https://perma.cc/M67W-6Y9L]
(discussing the 13-day rule, which is used in embryonic stem-cell research). The thirteenday rule provides that no research should be conducted on embryos once they reach thirteen
days old. Id. Around the 13-day mark is when embryos begin to develop early human
features where cells begin to differentiate. Id. At this time the embryo also begins to develop
circulatory paths to connect to the womb in order obtain nutrients from the mother. Id.
Scientists have widely accepted this rule as the furthest one should study an embryo before
ending the study and destroying the embryo. Id.
166
See generally Kearl, supra note 161 (describing the Dickey-Wicker Amendment as the
sole barrier to further embryonic research).
167
See Mailee R. Harris, Note, Stem Cells and The States: Promulgating Constitutional Bans on
Embryonic Experimentation, 37 VAL. U. L. REV. 243–46 (2002) (providing statistics on IVF use).
161
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federal ban should be struck to make way for the implementation of
modern, forward-looking law that can adequately address the funding
and regulation of CRISPR.168
B. The Solution: Current Bills and Proposed Approaches
Others in the legal community agree that the first step to a solution
involves repealing the Dickey-Wicker Amendment.169 However, there is
disagreement on how to proceed after a successful repeal. 170 Proposals
range from an all-out ban on funding CRISPR, to others suggesting the
forming of committees or expanding authority of the Food and Drug
Administration.171 Part III.B critiques the effectiveness and plausibility of
different approaches to regulate and fund CRISPR. 172
The impact of the 21st Century Cures Act on CRISPR cannot be fully
understood at this point.173 One of the goals of the act is to take a more
aggressive approach to cancer research.174 The act includes an investment
In 2001, the number of frozen embryos for the purposes of IVF was at least 188,000. Id. at
245–46.
168
See Zaret, supra note 107, at 1831 (recommending the elimination of the federal ban on
funding embryonic research).
169
See, e.g., id. (suggesting to lift the ban on embryonic research).
170
See, e.g., id. (proposing a new federal agency similar to what is in place in the United
Kingdom, called the Human Fertilisation and Embryology Authority (HFEA)). The author
continues by recognizing that lifting this ban would “open the door for regulatory
framework” to be put in place. Id. This proposal follows with a three-step proposal for how
to continue. Id. Others, meanwhile recognize that the Dickey-Wicker Amendment prohibits
embryonic research funding by the government. Sarah Ashley Barnett, Comment: Regulating
Human Germline Modification in Light of CRISPR, 51 U. RICH. L. REV. 553, 576 (Jan. 2017).
171
See Zaret, supra note 107, at 1828–31 (likening a potential agency to HFEA. See also
Barnett, supra note 170 (suggesting an expansion of the FDA); infra Part IV (providing this
Note’s proposal). The act would then direct funds to CRISPR research in four ways. Id. First,
the language should focus funds to studies seeking to improve CRISPR itself and for human
application in clinical trials. Id. Second, the legislation would bar research on viable human
embryos. Id. We simply do not have enough information on the true ramifications of such
an act and there is no agreement as to whether we should ever take that step. Id. Third, no
funds will be provided to studies that seek to accomplish cosmetic goals such as changing a
child’s eye color. Id. Additionally, using CRISPR in an agricultural setting is generally
permitted, but is beyond the scope of this discussion. Id. Finally, if research institutions
violate the guideline of using CRISPR on a viable human embryo, funding for that study will
be revoked and future funding will be temporarily revoked. Id.
172
See infra Part III.B (analyzing approaches from various law review articles on their
plausibility and effectiveness if pursued).
173
See generally Obama Signs 21st Century Cures Act into Law, ASSOCIATED PRESS (Dec. 13,
2016),
https://www.statnews.com/2016/12/13/21st-century-cures-obama-signs/
[https://perma.cc/C53E-2SGJ] (showing how the act was only recently signed).
174
See generally Weekly Address: Pass the 21st Century Cures Act, OFFICE OF THE PRESS
SECRETARY (Dec. 3, 2016), https://www.whitehouse.gov/the-press-office/2016/12/03/
weekly-address-pass-21st-century-cures-act [https://perma.cc/66RJ-XY43] (stating the
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in former Vice President Joe Biden’s Cancer Moonshot program. 175 While
research using CRISPR may see some of these funds, it is difficult to
determine how much, if any at all, will go to CRISPR.176 Because CRISPR
is not mentioned specifically in the act, a subsequent act may need to be
implemented to assure adequate funding is being directed to CRISPR
research.177 In the alternative, the implementation of the 21st Century
Cures Act could be guided by the act proposed in this Note when it comes
to directing research funding. 178 This may be possible because the 21st
Century Cures Act similarly empowers the National Institutes of Health
in dispersing research grants.179 Ultimately, the 21st Century Cures Act
does not detrimentally affect the act proposed in this Note, but reinforces
the idea that investing in medical research is an issue susceptible to
compromise in a divided Congress.180
One offered proposal in the legal community to solve the ethical
issues related to CRISPR is through a congressionally-established

goals of the Act). In President Obama’s weekly address, he set out the goals of the 21st
Century Cures Act (also known as the Beau Biden Act) in a statement of support before the
bill had been passed. Id. In addition to seeking out remedies to opioid addiction, the act
aims to find cures for Alzheimer’s Disease and cancer generally. Id.
175
See generally id. (reiterating the goal for the United States to lead the charge in finding a
cure for cancer). The president goes on to emphasize how many diseases such as
Alzheimer’s and Epilepsy touch so many lives and that it made compromise possible in this
act. Id.
176
See Sheila Kaplan, Senate Passes Landmark 21st Century Cures Act—But It Will Take Years
to Implement, STAT (Dec. 7, 2016), https://www.statnews.com/2016/12/07/21st-centurycures-senate-passes/ [https://perma.cc/Q755-J6MR] (noting the lengthy process of
implementing the 21st Century Cures Act). However, the act will be difficult to implement
and it may take a considerable amount of time to work out all of the details. Id.
[T]he Cures Act, nearly 1,000 pages long, does not lay out many
deadlines. The dirty secret is it’s going to take many years to implement
these things,” said Bethany J. Hills, who runs the FDA practice at Mintz
Levin Cohn Ferris Glovsky and Popeo. “There are many provisions
requiring guidance, and whenever Congress has mandated that FDA
provide guidance on something, the FDA historically is perpetually late.
Id. The FDA will require a lot of time to implement regulations for a lengthy bill such as this.
Id.
177
See H.R. 34-114, Dec. 8, 2016 (providing the language of the bill signed December 13,
2016).
178
See Regaledo, supra note 1 (discussing the ethical concerns related to CRISPR that
should guide and direct the government funds to the appropriate research projects).
179
See Kaplan, supra note 176 (discussing the effect of the 21st Century Cures Act on the
National Institutes of Health). The Act will increase the NIH’s budget by $4.8 billion. Id.
This also likely provides more certainty for the NIH with an incoming administration that
presented numerous uncertainties about the organization’s future. Id. Cuts to both
regulations and budgets send mixed messages. See generally id.
180
See Office of the Press Secretary, supra note 174 (providing President Obama’s statement
describing the 21st Century Cures Act as one of compromise).
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committee.181 This committee would attempt to accomplish two goals. 182
First, the committee would be in charge of considering ethical concerns
related to specific CRISPR studies, obtain public opinion on the matter,
and frame potential legislation.183 Such a committee may be useful in
drafting the official legislation similar to the legislation being proposed in
this Note.184 However, the formation of a committee would otherwise be
unnecessary.185 Congressmen are largely qualified to intake public
opinion from their constituents and to consider the relevant lawmaking
process, but the same cannot be said for the ability to evaluate scientific
proposals.186 The NIH is already equipped to do this, because they are the
entity that approves and distributes grants for scientific and medical
research.187 Specifically, the Recombinant DNA Advisory Committee
(RAC) of the NIH approves clinical studies involving DNA (which would
include CRISPR).188
The second committee goal from this proposal would be to “consider
the creation of a standing federal entity that would have authority over
both public and private sectors” and would set standards for research.189
Again, this is quite similar to functions carried out by the NIH. 190
Additionally, it is unlikely that the current political climate would allow

181
See Zaret, supra note 107, at 1831 (proposing a Congressional committee that could sift
through potential legislation as well as assist in establishing a new federal agency). The
formation of a committee could funnel policy through representatives and senators that have
more expertise in science and medicine than the entire body of Congress. Id.
182
See id. (calling for a committee that would review legislation and possibly help in the
formation of a new federal agency to handle CRISPR and all that comes with it).
183
See id. (suggesting that this committee could serve as a filter for the drafts of proposed
legislation coming in, not unlike the current committee system for bills).
184
See generally id. (inferring that committees mark up legislation as part of the bill passage
process in both houses of Congress, and a similar function would likely be performed here).
185
See infra Part IV (stating why Congress should allow the NIH to make decisions about
the ethical nature of each study within the boundaries set by lawmakers).
186
See infra Part IV (noting how the NIH already has medical and ethical experts that make
such considerations a part of the grant-awarding process).
187
See generally NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid
Molecules, NATIONAL INSTITUTES OF HEALTH (Apr. 2016), https://osp.od.nih.gov/wpcontent/uploads/2013/06/NIH_Guidelines.pdf
[https://perma.cc/MHX3-ZSAF]
(outlining safety considerations made by the NIH). These guidelines apply to all research
conducted in the United States. Id.
188
See id. (providing the lengthy list of guidelines reviewed by RAC).
189
See Zaret, supra note 107, at 1832 (stating that Congress would lay out the ethical
boundaries for this new agency). The proposal in this Note specifies those ethical boundaries
by stating which studies would be funded, which studies would not be funded, and the
consequence for violating such ethical boundaries. See also infra Part IV (providing a detailed
proposal).
190
See generally infra Part IV (contesting that the NIH is qualified for this task because it
already deals with ethical oversight of genetic research).
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for the creation of an entirely new federal agency. 191 The new
administration that took over in early 2017 has placed a high value on
gutting agencies and cutting budgets across the board. 192 The creation of
a new federal agency would inevitably cause the creation of new
government jobs.193 But, in a time where there may be a succession of
government hiring freezes, it begins to look bleak that a new agency could
be created.194 This is especially true for a potential agency that may
overlap duties with the already-existing NIH.195 Instead, a piece of
legislation that sets a government funding plan would have a higher
While budget cuts are currently being
likelihood of success.196
emphasized, the current administration has not ruled out shifting
spending from one agency to another.197
Another proposal to solve CRISPR-related issues is to introduce
legislation that would expand or reinforce the Food and Drug
Administration’s (FDA) role in regulating CRISPR. 198 With or without
new legislation, the FDA would be charged with the task of determining
what clinical trials, treatments, or technologies would be safe for the
public.199 The FDA does not explicitly cover CRISPR, and this may be
191
See, e.g., Eric Krupke, How We Got Here: A Shutdown Timeline, NPR (Oct. 17, 2013),
http://www.npr.org/sections/itsallpolitics/2013/10/16/235442199/how-we-got-here-ashutdown-timeline [https://perma.cc/G7FZ-ASY6] (chronicling the latest government
shutdown).
192
See, e.g., Glenn Thrush, Kate Kelly, and Maggie Haberman, Trump to Ask for Major Cuts
to EPA, Increased Spending for Military, THE BOSTON GLOBE (Feb. 27, 2017),
https://www.bostonglobe.com/news/politics/2017/02/26/trump-ask-for-major-cutsepa-increased-spending-for-military/bRLCI3ye7Ym0F4SNUNXo4H/story.html
[https://perma.cc/2QA4-AAEG] (cutting the EPA’s budget by an estimated two-thirds).
193
Cf. Presidential Memorandum Regarding the Hiring Freeze, THE WHITE HOUSE, OFFICE OF
THE
PRESS SECRETARY https://www.whitehouse.gov/the-press-office/2017/01/23/
presidential-memorandum-regarding-hiring-freeze
[https://perma.cc/K9Q7-8HMJ]
(analogizing that this would be off the table during a government hiring freeze).
194
See, e.g., id. (stating that this hiring freeze extended to all executive agencies).
195
See id. (inferring that a new agency is unlikely considering the memo states that the
reduction of the government work force is sought to be made permanent through attrition).
196
See infra Part IV (making the case for legislation that would allow for additional or fewer
funds to be applied to CRISPR at set time periods).
197
See Thrush, supra note 192 (“requesting tens of billions of dollars in reduction for the
Environmental Protection Agency and State Department”).
198
See Zaret, supra note 107 (noting the FDA’s “limited oversight” in this area currently).
See also Barnett, supra note 170, at 580 (recommending the expansion of FDA oversight).
199
See Consumer (Biologics), FDA (Sept. 18, 2013), https://www.fda.gov/
BiologicsBloodVaccines/ResourcesforYou/Consumers/default.htm
[https://perma.cc/
D7NL-XZU8] (defining biologics as “biological products [that] include a wide range of
products such as vaccines, blood and blood components, allergenics, somatic cells, gene
therapy, tissues, and recombinant therapeutic proteins”). CRISPR could fall under “gene
therapies” in some instances. Cf. id. (pointing out that CRISPR, as a new technology, could
be categorized as different types of medical items).
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because the potential uses for CRISPR are wide-ranging.200 This does raise
interesting questions for how the FDA will classify CRISPR. 201 Should the
evaluation process for approval move forward as it does for biologics,
treatments, medical devices, or as a new category altogether?202 While the
FDA does have experience in this area, Congress’s focus should first be on
the NIH.203 This is because the FDA will have nothing to approve if the
studies and clinical trials are not occurring.204 Similarly, the NIH is a more
effective body for preventing human germline editing before society is
ready because they are the entity that sets guidelines for grant-receiving
studies and would use those guidelines to direct government funds. 205
When it comes to privately-funded research, the FDA may have more
control over whether such medical and genetic practices ever see the light
of day.206 The legislation proposed in this Note deals exclusively with
publicly-funded research for CRISPR. 207 Additionally, it may be wise to
begin considering regulatory approaches that directly addresses how
intentional human germline editing would be approached. 208 However,
the use of CRISPR in adults and children to cure disease in single
individuals is more pertinent at this time.209 This is because the emergence
of clinical trials to accomplish just that in 2018 and beyond is pushing such
uses of CRISPR from the theoretical realm into the practical. 210
200
See Zaret, supra note 107, at 1829 (stating that the FDA has jurisdiction over gene-editing
procedure approval). But see Barnett, supra note 170 (noting that the FDA does not have
oversight over human germline editing). This is because human germline editing is still
banned in the United States. Id.
201
See Barnett, supra note 170, at 580 (realizing the different ways that CRISPR treatment
could be classified when applying for FDA approval).
202
See id. (bringing to light the fact that the CRISPR approval process by the FDA may
differ based on the type of treatment).
203
See (commenting on the FDA’s role in approving CRISPR experiments). But see infra
Part IV (recommending power be reinforced at the NIH and member institutions).
204
See generally Zaret, supra note 107 (reflecting the FDA’s role in approving treatments
that are theoretically ready for human application, which CRISPR is approaching in a limited
sense).
205
See generally NIH Guidelines, supra note 187 (covering all research, publicly funded or
not, on the ethical and safety concerns of the NIH).
206
Cf. NIH Guidelines, supra note 187 (referencing the distinct roles of the NIH and FDA
when it comes to approving and using public funds for research, compared to approving a
treatment or technology for human use).
207
See infra Part IV (clarifying that NIH guidelines cover all relevant research conducted
in the United States, but has more exclusive control over research receiving grants).
208
See generally NAT. INST. OF HEALTH, supra note 21 (referencing the fast pace of genetic
research, which would lead to a cause for forward-looking legislation beyond what is
immediately at hand).
209
See infra Part IV (arguing that an investment in public health and trying to cure
debilitating diseases should be the force pushing this legislation through Congress).
210
See Regaledo, supra note 1 (discussing the potential uses of CRISPR in 2017). See also
Mullin, supra note 40 (showing the direction of clinical trials).
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Again, expansion of a federal agency seems unlikely under the current
administration, but the redirection of funds may be more likely.211 It could
be argued that legislation endorsing human germline editing would not
gain enough support to be passed by Congress, and that would likely ring
true at this time.212 However, the use of CRISPR in adults as well as other
non-human-germline-editing methods raises fewer issues.213 This is
especially true when the benefits are so tangible as compared to previous
gene editing technologies which were slow and inaccurate.214
As stated above, CRISPR presents multiple issues that must be
confronted.215 Questions about ethics, previous legislative amendments,
financial considerations, scientific progress, the multiple uses for CRISPR
across medicine, agriculture, and pharmaceuticals pose a unique
challenge.216 Introducing new legislation allows lawmakers to attack
many, if not all, of these problems at once.217 This is because of the very
nature of a legislative bill.218 Legislators are naturally positioned to work
with policy and conflicting interests among citizens, business entities, and
public institutions.219 Therefore, a bill introduced in the United States
Congress would be the most logical and natural place to address

211
See generally Krupke, supra note 191 (emphasizing how the additional cost of creating a
new federal agency is not plausible at this point in time).
212
See generally Zaret, supra note 107 (referring to questions about human germline editing
in humans before the technology is perfected further).
213
See, e.g., Chestnut, supra note 19 (comparing old gene-editing technologies such as
TALENs to CRISPR, which adds promise through speed, affordability, and accuracy).
214
See Kahn, supra note 44 (stating various ethical concerns in a Congressional hearing to
the House Committee on Science, Space, and Technology). Concerns are shared with many
scientists and include frivolous uses as well as misuse in humans. Id. Such misuses at this
point in time would include consent issues when permanently editing the genes of future
generations that have not yet been conceived. Id.
215
See Regalado, supra note 34 (noting the debate for what humans should and should not
use CRISPR).
216
See Regalado, supra note 34 (reviewing the ethical concerns). See also Skerrett, supra note
49 (citing to the economic concerns associated with the cost of gene therapy using CRISPR).
See also Maywa Montenegro, CRISPR is Coming to Agriculture – With Big Implications for Food,
Farmers, Consumers, and Nature, ENSIA (Jan. 28, 2016), http://ensia.com/voices/crispr-iscoming-to-agriculture-with-big-implications-for-food-farmers-consumers-and-nature/
[https://perma.cc/SD59-BSAR] (discussing the use of CRISPR in a variety of agricultural
settings).
217
See generally Introduction and Referral of Bills, UNITED STATES CONGRESS
https://www.congress.gov/legislative-process/introduction-and-referral-of-bills
[https://perma.cc/C5LP-QRQ3] (explaining the nature of introducing legislation as a bill).
218
See generally id. (discussing the drafting of a bill’s language).
219
See generally What is a Representative?, THE UNITED STATES HOUSE OF REPRESENTATIVES
http://www.house.gov/content/learn/ [https://perma.cc/75BA-5U8D] (explaining how a
member of the House of Representatives is meant to represent their constituents in their
respective congressional district and advocate for their concerns).
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CRISPR.220 Legislators are also in the unique position of answering to
constituents.221 CRISPR’s ethical issues are ones that should require input
from the public.222 Controversial ethical questions in science have never
been ones in which our government decides for us.223 So if we are to
conduct a true “worldwide conversation,” the United States’ decisions
will carry considerable weight for the rest of the world.224 What legislators
must do is determine the language of the legislation. 225
Comprehensive legislation is also a better avenue, because there is still
progress to be made in CRISPR’s accuracy and overall potential, further
research should be directed toward perfecting CRISPR. 226 Eliminating the
potential for problems in the human application of CRISPR is a necessary
step to making this a treatment option a norm in medicine. 227 Continuing
progress in perfecting medical treatment should always be encouraged,
but this is especially true for CRISPR, which is only four years old as a
technological tool.228 Additionally, the prospect of curing or treating
genetic diseases that have such a profound impact on our society is more
likely to encourage compromise than many other issues that we face
today.229 The combination of these issues should create an urgency and

220
See id. (describing the position of a member of congress and their connection to their
constituents). See also infra Part IV (stating the importance of public input into a controversial
issue such as CRISPR).
221
See generally id. (commenting on a Congressman’s purpose to serve the people).
222
See generally Doudna, supra note 13, at 11:17 (advocating for a public conversation
among citizens and figures of authority in the fields of law, ethics, and science).
223
See generally Emerging Biotechnologies and the Role of the NIH RAC, NATIONAL INSTITUTES
OF HEALTH (June 16, 2016), http://osp.od.nih.gov/under-the-poliscope/2016/06/
emerging-biotechnologies-and-role-nih-rac [https://perma.cc/NWF7-UXXF] (announcing
the altering of NIH guidelines that determine how research studies obtain grant funds from
the NIH). Even regulations go through a public comment period before being enacted. See
generally id.
224
See generally Doudna, supra note 13, at 13:38 (implying that our society must come to
some level of agreement on what acts are acceptable before proceeding with further research
involving embryos).
225
See Introduction and Referral of Bills, UNITED STATES CONGRESS (last visited June 18, 2017),
https://www.congress.gov/legislative-process/introduction-and-referral-of-bills
[https://perma.cc/C5LP-QRQ3] (noting the job of lawmakers and congressional lawyers to
work on the specific language of a bill).
226
See, e.g., Begley, supra note 154 (discussing CRISPR’s low degree of error, which still
needs to be improved).
227
See id. (noting the promise involved in one particular use of CRISPR).
228
See id. (implying that the technology needs to improve its accuracy before application
in humans).
229
See generally NATIONAL INSTITUTES OF HEALTH https://www.genome.gov/
10001204/specific-genetic-disorders/ [https://perma.cc/BVF4-WEVP] (providing a nonexhaustive list of many of the most common diseases that have a “genetic component”).
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common purpose to accomplish the difficult issues presented by
CRISPR.230
One common thread from the proposals discussed above is that the
regulation of CRISPR is discussed primarily as a way to curb potential
harms from the technology’s development. 231 The potential benefits of
curing diseases with CRISPR do not go unrecognized by anyone. 232
However, regulation should not be seen purely as a barrier, but also as a
facilitator.233 It is illogical that research would move forward without the
relevant ethical concerns being sorted out for the long term with
scheduled periods for reassessment.234 That is what this contribution aims
to accomplish: setting the table for legislation that serves as an ethical
problem-solver and an enthusiastic endorsement for CRISPR research. 235
New legislation has the unique ability to perform this balancing act. 236
IV. CONTRIBUTION
This contribution is separated into two subsections. 237 Part IV lays out
the goals and intentions of the proposed legislation. 238 Part IV also
outlines repealing the Dickey-Wicker Amendment and then the ethical
and scientific guidelines that will direct the NIH and individual research
institutions in funding research on CRISPR.239 Part IV.B addresses a few
230
See generally The Genetic Disease Foundation (GDF) Encourages Americans to Know Their
Genes at KnowYourGenes.org in Observance of World Rare Disease Day, PR NEWSWIRE (Feb. 28,
2010), http://www.prnewswire.com/news-releases/the-genetic-disease-foundation-gdfencourages-americans-to-know-their-genes-at-knowyourgenesorg-in-observance-of-worldrare-disease-day-85763017.html [https://perma.cc/8QKQ-RBFW] (stating that over 12
million individuals suffer from genetic diseases of various forms today in the United States).
231
See Zaret, supra note 107, at 1832–38 (citing the primary downsides of regulation as
politicizing science and the effects on procreative autonomy). See also Barnett, supra note 170,
at 581 (permitting the use of CRISPR, even in human germline editing). This proposal sets
the standards for approving CRISPR techniques but does not discuss government funding
of such contributing research). Id.
232
See Barnett, supra note 170 (recognizing not only the benefits of CRISPR used on adults,
but also the benefits of human germline editing when ethically sound).
233
See infra Part IV (emphasizing the benefits to federal funding for CRISPR research,
which would gain more support if regulations were put in place to satisfy the public’s
concerns).
234
See infra Part IV (proposing an approach that would allow for reassessment of human
germline editing in the United States).
235
See infra Part IV (laying out ethical boundaries to facilitate research and restrict
unethical practices).
236
See infra Part IV (proposing a two-goal piece of federal legislation).
237
See infra Part IV (discussing the proposed legislation and then counterarguments).
238
See infra Part IV (laying out what this proposed piece legislation hopes to accomplish,
from repealing the Dickey-Wicker Amendment to implementing guidelines for how CRISPR
research will be addressed in the short-term).
239
See infra Part IV (outlining the proposition in terms of two larger parts).
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arguments likely to be raised against this proposal.240 This subsection
intends to differentiate and reason why this specific proposal would be
more efficient and effective than alternative options. 241
In order to facilitate future research involving CRISPR, the ethical
concerns must be addressed immediately.242 This can be done most
efficiently through legislation passed by Congress with a primary goal of
investing in public health.243 Keeping in mind the numerous potential
uses for CRISPR, this Note will only focus on one aspect of this proposed
act: human application in a clinical trial setting.244 The scope of this
legislation will therefore be tailored to the relevant ethical issues related
to human application with the goal of curing and treating diseases and
inherited genetic conditions.245
A. The Act
The first part of this act will repeal the Dickey-Wicker Amendment.246
Second, to relieve concerns about the perceived dangers of living in a
CRISPR world, this legislation should be narrowly tailored to achieve the
goal of improving public health in America.247 That is why this legislation
should fund two types of research involving CRISPR. 248 Next, this
legislation should direct funds that more directly achieve the goals of the
legislation.249 More specifically, this act should fund research studies that
240
See infra Part IV.B (addressing three counterarguments). Specifically, the necessity for
such legislation, the cost concerns, and the scope of the act. Id. See also Alison Peck, ReFraming Biotechnology Regulation, 72 FOOD & DRUG L.J. 314, 333, 339 (reflecting the growing
need and support for new legislation on biotechnology).
241
See infra Part IV.A (noting the unique advantages lawmakers have to address these
many issues).
242
See Kahn, supra note 44 (telling Congress the importance of resolving these ethical
disputes is essential to realizing CRISPR’s full potential for medical patients).
243
See UNITED STATES CONGRESS, supra note 225 (reiterating the flexibility in changing the
law through legislation).
244
See generally Regalado, supra note 34 (discussing the CRISPR landscape in the world of
ethics).
245
See NATIONAL INSTITUTES OF HEALTH, supra note 153 (providing information on three
clinical trials scheduled in China). Clinical trials are taking place in China, but are
progressing at a slower pace in the United States. Id.
246
See The Balanced Budget Downpayment Act of 1996, supra notes 65–66 (providing the
broad language of the amendment).
247
See generally Budget, NATIONAL INSTITUTES OF HEALTH (last visited June 3, 2017),
https://www.nih.gov/about-nih/what-we-do/budget [https://perma.cc/P7AU-VHQA]
(reflecting the $32.3 billion dollars the NIH invests in competitive grants each year). That
money from the consolidated appropriations act is the only funding coming from the
American taxpayer. Id.
248
See, e.g., Begley, supra note 42 (exemplifying a clinical trial setting for research).
249
See Zaret, supra note 107 (specifying that funding should be directed toward grants for
research on CRISPR clinical trials).
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intend to treat or cure genetically influenced diseases and conditions. 250
There will be no prioritization of which ailments should receive more or
less attention through amount of funds or which studies will be funded
earlier rather than later.251 The NIH and individual research institutions
are far more qualified to make such determinations than lawmakers. 252
Accordingly, deference should be provided to the NIH and its member
institutions.253 Further, this Note recommends that it should be made
clear in the language of the bill that no ailment is too small to receive
attention from CRISPR research.254 While the destructive nature of
diseases such as Muscular Dystrophy and Alzheimer’s throughout our
society is well-documented, it is not the job of the legislature to determine
which populations of patients are in more or less need of aid.255 Similarly,
lawmakers are largely unqualified to determine which ailments have the
most hope of receiving a treatment or cure from CRISPR. 256 This act is
meant to empower the scientific community, not to step on its feet.257
Next, this act would have to set guidelines for not only what types of
studies would be included and excluded from eligibility for funding. 258 It
would also need to identify specific types of studies that would be
prohibited whether the studies were receiving funding from this act or
250
See, e.g., NAT. INST. OF HEALTH, supra note 153 (exemplifying different clinical trials in
China planned to research various forms of cancer).
251
See Doudna, supra note 13, at 7:53 (showing the promise of using CRISPR on diseases
that affect the blood). Jennifer Doudna believes that diseases of the blood will be researched
heavily early on because of the higher level of access CRISPR has to blood cells. Id. She also
believes that CRISPR therapies could arise within about ten years. Id.
252
See generally Understand NIH: Finding the Right Fit for your Research, NATIONAL
INSTITUTES
OF
HEALTH,
http://grants.nih.gov/grants/understanding-nih.htm
[https://perma.cc/K4YV-2J33] (introducing a background into the NIH’s grant program).
253
See generally id. (emphasizing the NIH’s broad and deep history in determining a
study’s fitness for grant funding). See also Ben Merriman, “Editing”: A Productive Metaphor
for Regulating CRISPR, 15 AM. J. OF BIOETHICS 62 (Dec. 2, 2015) (stating that “regulation is a
metaphorical practice”). “In most cases, regulation involves drawing an analogy between
something new in science and something that is already regulated.” Id.
254
See generally NAT. INST. OF HEALTH https://www.genome.gov/10001204/specificgenetic-disorders/ [https://perma.cc/BVF4-WEVP] (showing that the number of genetic
diseases is large). There is no legitimate way to differentiate between and prioritize treating
one disease over another. Id.
255
See, e.g., HIV and AIDS in the United States of America, AVERT (updated July 22, 2016),
http://www.avert.org/professionals/hiv-around-world/western-central-europe-northamerica/usa [https://perma.cc/2ARK-YMGW] (reflecting the 1.2 million people inflicted
with HIV/AIDS in the United State in 2013).
256
See Kahn, supra note 42 (stating that different groups need to come together to
contribute in order to solve these problems).
257
See Regaledo, supra note 244 (reiterating the intent of this proposal to facilitate research
involving CRISPR to a greater degree).
258
Cf. 81 Fed. Reg. 15,315 (Mar. 22, 2016) (Providing the language of the NIH’s newly
adopted guidelines for awarding research grants).
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from private entities.259 Conducting research on viable human embryos
would be entirely prohibited by this act until sufficient progress was made
through research that a reassessment would be warranted. 260
As a final consideration, what consequences should be faced by those
institutions that engage in research on what some would consider
frivolous, or purely cosmetic uses of CRISPR?261 This would be addressed
two-fold.262 First, institutions that use private funds to research CRISPR’s
potential as a cosmetic tool would receive no penalty because no misuse
of government funds occurred.263 Second, and most importantly,
institutions that conduct research using CRISPR on viable human
embryos would receive monetary sanctions and the research project
would be terminated.264 This is arguably a harsh penalty for an institution
not partaking in the use of government funds directly. 265 However, one
of the central purposes of this legislation is to dissuade and prevent
research that could result in irreparable harm and is still considered to be
unethical by some.266 If institutions that apply for funds with outward
intentions that meet the above criteria, but in fact use the funds to study a
non-included purpose of CRISPR, possible sanctions could be enforced.267
This does not appear to be a significant concern at the present time, but
the institution would likely have their funding revoked, and would be
reviewed further according to NIH guidelines. 268
259
See Intellia, supra note 27 (discussing two companies competing to use CRISPR in
clinical trials).
260
See generally Abumrad & Krulwich, supra note 35 (moving in the direction of Jennifer
Doudna’s proposal that we should not be editing viable human embryos until we know
much more about the process, and after coming to a societal consensus on how far we should
go with gene editing).
261
See, e.g., Abumrad & Krulwich, supra note 35 (discussing the theoretical possibility of
turning a Chihuahua into a Great Dane by using CRISPR).
262
See supra Part IV (breaking down the contribution’s proposal into two parts).
263
See, e.g., Intellia, supra note 25 (exemplifying a company that will be using CRISPR in
various settings). Intellia was founded by co-inventor of CRISPR, Jennifer Doudna. Cf. id.
Intellia made its initial public offering (IPO) earlier in 2016. Id. See also Editas, supra note 25
(adding more information about the company’s goals in using CRISPR).
264
See, e.g., Begley, supra note 42 (exemplifying an institution that could theoretically be
penalized in such manner). Although the University of Pennsylvania has not been awarded
the distinction of housing this study, researchers from the university were the ones that
received approval from the NIH. Id.
265
Cf. Collins, supra note 64 (stating a necessity to combat the ethical concerns held by
many; without repercussions, oversight is less likely to be taken seriously).
266
See Doudna, supra note 13, at 11:55 (raising concerns about whether our society is ready
for human germline editing).
267
See, e.g., Abumrad & Krulwich, supra note 35 (using examples such as changing the
species of a dog or raising extinct species of animals like the wooly mammoth).
268
See generally Begley, supra note 42 (describing the first clinical trial application to be
approved).
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B. Commentary
Many may argue that this act would be unnecessary because the NIH
has already amended their guidelines to accommodate CRISPR.269 Indeed,
the NIH amended their guidelines in 2015 after previously suggesting it
would not do so.270 However, this act is not simply a directive to the
It is instead Congress taking considerations on how a
NIH.271
controversial piece of technology will be handled by independent research
institutes.272 How research institutes will handle ethical considerations as
well as what types of studies will be funded by the NIH, and deciding
what types of studies will still be impermissible with private funding
remain critical issues.273 Studies are becoming more common, and
scientists have been successful in altering traits in human cells. 274 It seems
to be only a matter of time before treatments and cures are on the
horizon.275 Therefore, a legislative plan should be put in place for making
such medical treatments affordable and available. 276
The national debt and the use of taxpayer money are hot issues in
today’s politics.277 In turn, both issues have been considered in the
formation of this proposal.278 There is tremendous research on the
monetary cost of a mentally and physically unhealthy population in
America.279 This act is certainly not capable of curing the country’s
numerous ailments overnight, but as a long-term investment, an act like
269
See 81 Fed. Reg. 15,315 (Mar. 22, 2016) (reflecting the recent amendments to the NIH
guidelines which were implemented in order to accommodate CRISPR).
270
See Collins, supra note 64 (stating that the NIH has no intention to become involved with
gene editing at any point in the near future).
271
See NAT. INST. OF HEALTH, supra note 245 (reiterating the true purpose of the proposed
act).
272
See id. (putting trust in Congress partly because of its unique relationship with the
American people, who should be providing their input on this issue).
273
See generally Understand NIH, supra note 252 (showing the task set out the NIH and the
NIH’s partner institutions of determining which studies will receive federal research grants
from the NIH).
274
See, e.g., Begley, supra note 154 (discussing progress in a study researching Sickle Cell
in mice).
275
See generally Begley, supra note 42 (discussing the steps being taken to take CRISPR to
human trials).
276
See Skerrett, supra note 49 (reflecting concern about CRISPR treatments becoming
available to only the wealthy).
277
See Jake Miller, Issue Brief: Debt and Deficit, CBS NEWS (October 1, 2012),
http://www.cbsnews.com/news/issue-brief-debt-and-deficit/ [https://perma.cc/H3PDL5KA] (highlighting concerns about mandatory spending contributing toward the deficit).
278
Cf. NIH, supra note 247 (noting that the NIH receives about $31 billion in funding
annually).
279
See, e.g., MAYO CLINIC HEALTH SOLUTIONS http://www.tcyh.org/employers/
downloads/Extra_MayoCostOfHealth.pdf [https://perma.cc/XB8S-V6DU] (stating that
employee illness cost employers $47 billion in productivity loss).
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this has the potential to put more money in the pockets of citizens. 280 A
healthier population logically leads to a healthier and more vibrant
economy at the cost of a short-term investment.281
One might criticize this proposal as one that comes woefully short of
addressing all of the relevant issues faced with CRISPR, and that
individual would not be wrong in saying so. 282 The ethical issues are
numerous, the uncertainty in the technology remains, and the potentially
beneficial uses of CRISPR grow by the day.283 However, the issues this
proposed legislation raises and attempts to remedy are narrow. 284 Ideally,
similar narrowly-tailored acts would follow to address concerns raised in
other fields such as animal rights, world hunger, and agriculture. 285 But
this act is intended as a remedy to the ailments of public health, and
CRISPR is better positioned to accomplish that goal than any other
scientific discovery of our time.286
V. CONCLUSION
After the advent of CRISPR/Cas9, the scientific community is
clamoring not only about CRISPR’s medical potential, but also the
emanating ethical concerns. Some fear that editing the human germline is
dangerous. These types of changes to viable human embryos will be
passed down to later generations. There are also concerns about where
the technology is right now. There is still progress to be made in accuracy
and reliability before CRISPR can be used on humans on a large scale.
Others, however, are more concerned about challenges to be faced further
down the road such as keeping gene therapy costs low or having too much
control over the genes of our children.
See generally Anna Louise Sussman, Burden of Healthcare Costs Shifting to the Middle Class,
WALL ST. J. (Aug. 25, 2016), http://www.wsj.com/articles/burden-of-health-care-costsmoves-to-the-middle-class-1472166246 [https://perma.cc/KK94-H65H] (noting the rapidly
increasing healthcare costs for Americans, partly caused by health conditions).
281
See generally id. (reflecting the increasing amounts of money Americans are spending on
health care).
282
See Regalado, supra note 34 (discussing the numerous issues with CRISPR that are not
directly addressed here).
283
See, e.g., Begley, supra note 248 (exemplifying the continuing progress for treating
diseases of the blood with CRISPR). The article also notes that the technology is still being
perfected as it still has the potential for unintended genetic mutations. Id. “The errors
occurred in less than 0.10 percent of the cells tested, which is still a concerning number.” Id.
284
See supra note 181 (reiterating the focus of this proposal on the investment in funding
for clinical trials for CRISPR while other uses for CRISPR may be just as valid).
285
See generally Zaret, supra note 107 (proposing the introduction of a committee that
would sift through different bills pertaining to CRISPR).
286
See Chestnut, supra note 19 (discussing the overall purpose of this proposed act to be a
step toward curing and treating genetic diseases).
280
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The quickly advancing science surrounding CRISPR is outpacing the
relevant law by years, even decades. The Dickey-Wicker Amendment
remains as an obstacle for researchers that want to study CRISPR in
human embryos. These problems are most efficiently remedied by new
legislation introduced and enacted by Congress. Such legislation would
not only provide and direct funds to be utilized for research on CRISPR,
but it would also address many of the related ethical concerns. Congress
should introduce a bill that repeals the Dickey-Wicker Amendment.
Such a unifying cause, such as genetic illnesses, is sufficient reason to
come to a compromise on how to fully take advantage of this truly
revolutionary technology. Jennifer Doudna has called for a “worldwide
conversation” on the ethical considerations of CRISPR. The purpose of
which is that we, as a society, should decide what steps we are willing to
take to achieve such desired goals as curing and treating genetic disease.
The scientific community has come to a consensus on CRISPR’s benefits;
now it is time for lawmakers and our community as a whole to ensure that
this powerful tool will be utilized effectively and responsibly for the years
to come.
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